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ABSTRACT 
Immunoglobulin G (IgG) is central in mediating host defense due to its 
ability to target and eliminate invading pathogens. The fragment antigen 
binding (Fab) regions are responsible for antigen recognition; however the 
effector responses are encoded on the Fc region of IgG. IgG Fc displays 
considerable glycan heterogeneity, accounting for its complex effector 
functions of inflammation, modulation and immune suppression. 
Intravenous immunoglobulin G  (IVIG) is pooled serum IgG from multiple 
donors and is used to treat individuals with autoimmune and inflammatory 
disorders such as rheumatoid arthritis and Kawasaki’s disease, 
respectively. It contains all the subtypes of IgG (IgG1-4) and over 120 
glycovariants due to variation of an Asparagine 297-linked glycan on the Fc. 
The species identified as the activating component of IVIG is sialylated IgG 
Fc. Comparisons of wild type Fc and sialylated Fc X-ray crystal structures 
suggests that sialylation causes an increase in conformational flexibility, 
which may be important for its anti-inflammatory properties.  
                
CH3
CH2
Increased conformational flexibility of IgG Fc associated with  
  switch from pro- to anti-inflammatory activity
“open” IgG Fc“closed” IgG Fc
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Although glycan modifications can promote the anti-inflammatory properties 
of the Fc, there are amino acid substitutions that cause Fcs to initiate an 
enhanced immune response. Mutations in the Fc can cause up to a 100-
fold increase in binding affinity to activating Fc gamma receptors located on 
immune cells, and have been shown to enhance antibody dependent cell-
mediated cytotoxicity. This is important in developing therapeutic antibodies 
against cancer and infectious diseases. Structural studies of mutant Fcs in 
complex with activating receptors gave insight into new protein-protein 
interactions that lead to an enhanced binding affinity. 
             
Together these studies show how dynamic and diverse the Fc region is and 
how both protein and carbohydrate modifications can alter structure, leading 
to IgG Fc’s switch from a pro-inflammatory to an anti-inflammatory protein. 
 
 
IgG1 Fc Activating Fc receptor
CH2
CH3
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INTRODUCTION 
Immunoglobulin G Review 
The Immunoglobulin G (IgG) is a glycoprotein consisting of two heavy and two 
light chains that are covalently linked through a series of disulfide bonds [1]. This 
protein is further divided into two major components: the fragment antigen-binding 
regions (Fab) and the fragment crystalizable region (Fc). The Fab is a heterodimer 
consisting of a portion of the heavy chain (VH, CH1) and light chain (VL, CL) that are 
covalently associated via a disulfide bond between the residues Cys220 in IgG1 
and Cys131 in IgG2-IgG4 in the CH1 domain with a carboxy-terminal cysteine of 
the light chain [2]. The variable regions (VH and VL) are involved in direct binding to 
a specific antigen, whereas the Fc region interacts with several receptors on innate 
immune cells. The Fc is a homodimer connected to the Fab region through a 
flexible hinge (residues Glu216-Pro230 for IgG1), which is stabilized by two 
disulfide bonds (Cys229 and Cys 226) [3] (Fig. 1A). The light chain is further 
classified into κ and λ chains based on their CH1 domain sequence [4]. Each chain 
of the Fc contains constant CH2 and CH3 domains. The CH2 domain contains a 
single N-linked glycosylation site at Asparagine 297 (Asn297). This glycan 
contributes to the overall “openness” of this protein giving it a horseshoe shape 
(Figure 1A,B) [5]. Each domain of IgG has a characteristic immunoglobulin fold (Ig) 
in both the Fab and Fc domains (Fig. 1C, 1D).  They consist of two β-sheets 
comprised of anti-parallel β-strands sandwiched and stabilized by inter-chain  
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Figure 1. (A) Schematic structure of IgG1 and of an Asn297-linked N-glycan.  The 
biantennary glycan consists of a mannose (Man) and N-acetylglucosamine 
(GlcNAc) core that is usually fucosylated (Fuc),  and can be further modified by 
addtion of a bisecting GlcNAc, terminal galactose (Gal), or sialic acid (NeuNAc).  
(B) Ribbon diagram  of wild type Fc (PDB ID: 3AVE)  with glycans shown as sticks. 
(C) Topolgy diagram and ribbon diagram (D) of Ig fold of immunoglobulin constant 
region.  
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disulfide bonds [2, 4]. This folding creates loops BC, FG, and C’E in the CH2 
domain of the Fc that are known binding sites of Fc gamma receptors (FcγRs), 
whereas the complementarity determining region (CDR) loops are known binding 
sites for specific antigens and are therefore variable.  The constant domains of the 
Fc are conserved across each IgG subtype (IgG1-IgG4), however variability 
increases when it comes to the glycan chain[6, 7]. 
 
N-linked Glycan of IgG 
The Asn297-linked glycan is a complex carbohydrate, made out of a 
mannose (Man) and N-acetylglucosamine (GlcNAc) core that is usually 
fucosylated. This glycan can be additionally modified with a bisecting GlcNAc, 
terminal galactose, and/or sialic acid [8] (Fig. 1A). This glycan contributes about 2-
3% (4kDa) of the overall molecular weight of the IgG [7]. Due to glycan 
modifications and IgG subtypes there are over 120 glycovariants of IgG found 
circulating in human serum [9]. IgG1 is the most common of all subtypes with a 
circulating concentration of 10-15 mg/ml [7]. With respect to glycosylation, 
fucosylation is the most common, with about 70% of IgGs containing this 
modification. 50% are terminally galactosylated, with 35% containing 
agalactosylated (G0) species, 35% containing mono-galactosylated (G1), and 16% 
of the human pool containing digalactosylated (G2). 15% contains some form of 
sialylation; 11% mono-sialylated (S1) and 4% disialylated (S2) [10] (Table. 1). 
Removing the N-linked glycan leads to a dramatic change in Fc conformation and 
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abrogation of binding to any FcγR; however, aglycosylated Fc can bind the FcRn 
protection receptor [11], which recognizes the interface between the CH2 and CH3 
domains of each Fc chain [12], a site distant from the Asn297-linked N-linked 
glycan. Modification of this glycan is known to alter binding of Fc to FcγRs 
reflecting its importance when it comes to Fc function.  
 
Table 1. N-glycan composition of serum IgG  
 
Antibody-Dependent Cell-Mediated Cytotoxicity 
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an intricate 
process involving antibodies connecting the innate and adaptive immunity to attack 
and destroy invading pathogens and/or tumor cells. Effector cells are activated 
when antigen/antibody immune complexes (IC) bind activating Fc gamma 
receptors (FcγRs) expressed on the surface, thereby initiating a cascade leading to 
cell activation and ultimately destruction of target cells [13]. Three main activating 
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receptors involved in ADCC are FcγRI/CD64, FcγRIIa/CD32 (H131/R131), and 
FcγRIIIa/CD16 (F158/V158). FcγRI and FcγRIIa are found predominantly on the 
surface of macrophages, and FcγRIIIa on natural killer (NK) cells [13-15] (Fig. 3). 
FcγRIIIa and FcγRI are type I transmembrane proteins containing two or three 
extracellular C2-type immunoglobulin-like domains, respectively, and 
immunoreceptor tyrosine based activation motifs (ITAMs) on the cytoplasmic 
domain of a receptor-associated γ-chain. FcγRIIa has two extracellular domains 
and an ITAM motif on a single chain [15-17].   
 
There are multiple pathways activated in response to engagement of FcγRIIIa with 
ICs. ITAMs become phosphorylated by Src kinases creating a docking site for 
spleen tyrosine kinases (Syk). Activated Syk then goes on to phosphorylate 
phospholipase C-gamma (PLC-γ) which translocates to the membrane to cleave 
phosphatidylinositol 4,5-bisphosphate (PIP2) to make diacylglycerol (DAG) and 
inositol-1,4,5-triphosphate (IP3). IP3 goes on to cause an increase in intracellular 
calcium resulting in activation and mobilization of cells [18, 19]. Activation of Src 
kinases also results in phosphorylation of phosphoisitol 3-kinase (PI-3K) that goes 
on to phosphorylate PIP2, which becomes PIP3. PIP3 then recruits PLC-γ [2].  Syk  
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Figure 2. Cartoon representation of Fc gamma receptors (FcγRs). Activating 
FcγRs with immunoreceptor tyrosine based activation motifs (ITAMs; green) or the 
inhibitory receptor with an immunoreceptor tyrosine based inhibitory motif (ITIM; 
red).  
 
also activates Vav/Rho proteins involved in ADCC, however, the exact mechanism 
remains unclear [20, 21]. The signaling cascades described above are specific for 
FcγRIIIa – these mechanisms have not been confirmed for FcγRIa, FcγRIIa, or 
FcγRIIIb. Similar to FcγRIIa, FcγRIIb is a type I transmembrane protein with two 
C2-type Ig domains expressed on B cells, macrophages, neutrophils, and mast 
cells [15, 18, 22]. This receptor inhibits calcium influx, cell activation, and 
mobilization due to its immunoreceptor tyrosine-based inhibitory motif (ITIM). 
Crosslinking of cell surface receptors leads to recruitment of SH2 containing 
Immunoreceptor tyrosine based activation motif (ITAM) 
Immunoreceptor tyrosine based inhibitory motif (ITIM) 
Fc RI Fc RIIa Fc RIIb Fc RIIc Fc RIIIa Fc RIIIb 
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inositide phosphatase (SHIP), which hydrolyzes proteins involved in the PLC-γ, PI-
3K, and Vav/Rho pathways [18, 23]. 
  
Several killing pathways in response to the crosslinking of FcγRIIIa on NK cells 
have been characterized. The most widely known and accepted is the 
perforin/granzyme pathway that results in apoptosis of the target cell. The 
activated effector NK cell releases a perforin:granzyme complex which interacts 
with Mannose-6 phosphate receptor (MPR), a surface protein on target cells. This 
interaction leads to endocytosis of the perforin:granzyme complex in the target cell. 
Granzyme B, a serine protease, is then released into the cytosol, from endosomes 
containing both granzyme and perforin, by a perforin pore, leading to activation of 
caspases and apoptosis. Perforin activation can independently cause lysis and cell 
death [24]. Crosslinking of FcγRIIIA resulting from binding of antibody/target cell 
ICs on the surface of natural killer cells causes a transcriptional upregulation of 
Fas ligand (FASL). NK cells expressing FASL then go to kill target cells expressing 
the FAS receptor (CD95/ APO-1), inducing apoptosis [24, 25]. 
 
Mutations/Modifications to Enhance ADCC  
 A glycovariant known to greatly enhance ADCC is afucosylated Fc (α1,6 
linked fucose removed). Afucosylated Fc is a non-common form of IgG Fc that is 
produced in Lec13 cells that have decreased GDP-Man-4,6-dehydratase activity. 
IgGs expressed in these cells are shown to have decreased fucosylation by 80% 
compared to 98% fucosylated product when expressed in Chinese hamster ovary 
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(CHO) cells with normal GDP-Man-4,6-dehydratase activity [26-28]. The 
afucosylated product was found to have 100-fold higher binding to FcγRIIIa by both 
enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance 
(SPR) experiments when compared to fucosylated Fc [27-31]. Subsequently, this 
increase in binding affinity to one of the main activating receptors involved in 
ADCC also caused an increase in cytotoxicity of target cells [27, 32]. A key study 
by Shields et al. characterized the cytotoxic effects of afucosylated vs. fucosylated 
Fc. Anti-HER2 antibody hu4D5-8 expressed in Lec13 cells was used in an ADCC 
assay against human breast cancer cells SK-BR-3 expressing HER2. Effector 
peripheral blood mononuclear cells (PBMCs) from six donors expressing either 
FcγRIIIa (Val158/Phe158) or FcγRIIIa (Phe158/Phe158) were used at a 30:1 ratio 
(pBMC:SK-BR-3). A 53-fold increase in cytotoxic effects was observed when 
afucosylated Fc was used, in comparison to fucosylated Fc which directly 
correlated to the increase in binding affinity to FcγRIIIa [27]. In addition to these in 
vitro studies, in vivo studies also demonstrated that afucosylated Fc increased 
ADCC in mouse models. These studies also showed increased ADCC has a direct 
correlation to increased binding to activating FcγRs.  
 
Murine IgG2 has the highest binding affinity to FcγRs in comparison to human 
subtypes, of which IgG1 has the highest affinity [33]. When fucose is removed, the 
binding affinity of murine IgG2 to the inhibitory receptor (FcγRIIb) and activating 
receptor (FcγRIV) increased when compared to fucosylated IgG2. Post induction of 
melanoma lung metastasis, mice were treated with either fucosylated IgG2 or 
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afucosylated IgG2. The authors found that afucosylated Fc significantly decreased 
the number of tumor cells compared to its fucosylated counterpart which showed 
little to no effect [32].  
 
A study by Ferrara et al. also demonstrated the importance of fucosylation in 
relation to binding to FcγRs. Afucosylated Fc showed an increased binding to 
FcγRIIIa by surface plasmon resonance (SPR) [29, 30, 34]. In addition to showing 
increased binding, the authors solved high-resolution crystal structures of 
afucosylated Fc and fucosylated Fc in complex with FcγRIIIa. There were new 
carbohydrate-carbohydrate and protein-carbohydrate interactions observed in the 
afucosylated complex structure that were not seen in the fucosylated one. 
Specifically, GlcNAc1 on the Fc forms new hydrogen bonds with GlcNAc1 and 
GlcNAc2 of the N-linked glycan at site 162 of the receptor. Man3 of Asn162 on 
FcγRIIIa also forms hydrogen bonds with Gln295 (afucosylated Fc) and Lys128 
(FcγRIIIa), respectively, further stabilizing the complex. There was also a 
displacement of the Asn162 glycan in the fucosylated complex where there is an 
increase in distance of the carbohydrate interactions between that glycan and the 
Asn297 glycan of the Fc. This complex was key in understanding how removal of 
the core fucose allows better binding to the receptor.  
 
Although afucosylation is widely known to enhance ADCC both in vitro and in vivo, 
efforts have been made to increase FcγRIIIa binding through modification of the 
polypeptide, as opposed to glycan modification. Lazar et al. conducted a screen of 
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different combinations of mutants in the CH2 domain of known FcγR binding 
regions [35, 36]. A G236A/S239D/I332E (GASDIE) mutant Fc was shown to have 
70-fold enhanced binding to activating receptor FcγRIIa and enhanced 
phagocytosis in vitro. Mutants S239D/I332E (SDIE) and S239D/A330L/I332E 
(SDALIE) demonstrated enhanced ADCC and increased binding to activating 
receptor FcγRIIIA. The difference between these two Fcs is the A330L mutation. 
Addition of this mutation destroys complement-dependent cytotoxicity (CDC), 
which might result from A330 being in close to the C1q binding site, selecting for 
an ADCC response [37]. The published unbound structure of the SDALIE mutant 
did not show any significant changes in the known FcγR binding region although it 
was in an overall more open conformation when compared to wtFcs [38].  
 
Anti-Inflammatory Properties of IgG Fc 
In addition to eliciting inflammation, IgG Fcs plays a certain role in 
suppressing immune response. Throughout the years efforts have been made to 
treat autoimmune and inflammatory disorders such as rheumatoid arthritis and 
Kawasaki’s disease, respectively. One widely known treatment is intravenous 
immunoglobulin G (IVIG) therapy. Patients are administered 1g/kg of pooled IgG 
from the serum of various donors every few weeks to treat their disease and to 
suppress inflammation. Although this therapy is successful, it only works at high 
doses because sialylated Fc is the activating component in IVIG. Sialylation is not 
a common modificaation of IgGs, with only 11% mono-sialylated and 4% 
disialylated in the human serum. Additionally those who suffer from rheumatoid 
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arthritis have an even smaller amount of sialylated antibodies and a higher amount 
of agalactosylated species [39, 40]. Several in vivo experiments have shown that 
disialylated Fc is important and lead to various models proposed for its activation.  
 
K/BxN Mouse Model 
                 The K/BxN arthritis mouse model was a valuable tool used to study 
antibody therapies for autoimmune and inflammatory disorders.  K/Bxn mice were 
produced to have the arthritogenic T Cell receptor (TCR), KRN, and MHC class II 
allele Ag7 (I-Ag7), which results in joint inflammation reflective of human arthritis 
[41]. The KRN TCR recognized anti-glucose-6-phosphate isomerase (GPI) 
antibodies presented by MHC class II I-Ag7 on B cells. This lead to B cell 
expansion and secretion of GPI autoantibodies [41, 42]. Serum from these 
transgenic mice, or the injection of GPI autoantibodies into naive mice, is sufficient 
to induce inflammation [42]. 
 
This model was of central importance in characterizing IVIG. When inflammation is 
induced intravenously in mice, using K/Bxn serum, followed by administration of a 
high dose of IVIG (1g/kg), protection from inflammation is observed along with a 
visible decrease in joint inflammation [43, 44]. These results prompted the 
question: Why is such a high dose required for protection against inflammation? 
When IVIG was administered at a lower dose (0.33g/kg) protection was not 
observed, which suggested that only a small fraction of a specific species was 
responsible for anti-inflammatory protection [43, 44]. Additionally, when IVIG was 
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treated with neuraminidase (NA), an enzyme that removes sialic acid, and 
administered to mice after post-induction of inflammation, protection was not 
observed [43]. The same result was observed when the glycan was removed by 
peptide-N-glycosidase (PNGase) F [43].  
 
 IVIG IgG and IVIG Fc (papain digested) were enriched for sialylation using 
Sambucus Nigra (SNA) lectin, a lectin that binds preferentially to α2,6 linked sialic 
acids [45]. A smaller amount (.033g/kg) of SNA-enriched IgG and Fc was needed 
to initiate the same protective effect as unmodified IVIG IgG and Fc administered 
at 1g/kg [43, 44]. Fcs enzymatically sialylated with α2,6 sialyltransferase 
(ST6Gal1) also produced the same affect as SNA-enriched Fcs [46]. Although 
these experiments showed that Fcs that are mono-sialylated and disialylated were 
the active component in IVIG, the exact pathway is poorly understood.  
 
Role of DC-SIGN in the Anti-Inflammatory Pathway 
 Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
 (DC-SIGN) is a type II transmembrane protein that is calcium dependent and 
exists as a tetramer in the membrane of both macrophage and dendritic cells. It 
contains a carbohydrate recognition domain (CRD) that is the main binding site of 
sugars for this C-type lectin, and a neck region responsible for tetramerization, a 
transmembrane region, and cytoplasmic domain [47-49]. The mouse orthologue of 
DC-SIGN is specific intercellular adhesion molecule-3-grabbing nonintegrin-related 
1 (SIGN-R1)[50]. DC-SIGN is known to bind gp120 on the HIV viral spike, thereby 
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facilitating infection; however, only recently it was found to be involved in the anti-
inflammatory pathway and essential for IVIG function [46, 48].  
 
 A study published in 2011 identified DC-SIGN and FcγRIIB as key receptors of 
 the anti-inflammatory pathway mediated by sialylated Fcs [46]. Using the K/BxN 
model, inflammation was induced in wild type mice (SIGN-R1+), mice lacking the 
SIGN-RI receptor (SIGN-R1 -/-), and mice expressing hDC-SIGN (hDC-
SIGN+/SIGN-R1-/-), followed by treatment with a low dose of sialylated Fc (.03 
g/kg). The wild type mice showed a decrease in inflammation after five days of 
being treated with sialylated Fcs. No protective effect was observed upon 
administration of sFc to the SIGN-R1 -/- knockout mice; however, if hDC-SIGN was 
introduced in the SIGN-R1-/- knockout, sFc was effective in decreasing 
inflammation. This led to the conclusion that DC-SIGN/SIGN-R1 is involved in the 
anti-inflammatory pathway.  In addition to DC-SIGN, cytokines IL-4 and IL-33 were 
found to be a crucial part of this pathway. When IL-4-/- mice were administered sFc 
post treatment with K/BxN, inflammation was not suppressed. This was also the 
case when the IL-4 receptor (IL-4Rα),  expressed predominantly on effector 
macrophages, or the receptor associated signaling adaptor proteins (Stat6) were 
knocked out. Depletion of basophils known to release IL-4 was also able to 
abrogate the protective effect of IVIG and sFc. Additionally if IL-33 or its associated 
receptors (expressed on FcεR1+ leukocytes) were knocked out, protection was not 
observed. IL-4 upregulates FcγRIIB on the surface of monocytes, therefore this 
receptor was also considered a potential candidate for the anti-inflammatory 
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pathway [51]. In FcγRIIB -/- mice, IVIG-mediated protection from inflammation is 
not observed. Even though the key players involved in this pathway have been 
identified, the question remains to be asked if DC-SIGN is in fact the binding 
partner of sialylated Fc.  
 
NMR Analysis of Sialylated Fc 
Nuclear magnetic resonance (NMR) is a key tool used to understand 
dynamics of glycoproteins and polysaccharides. Specifically, NMR was used to 
study motions of IgG Fc glycans  (α1,3 branch and α1,6 branch) and also to 
observe changes in the branch resulting from sialylation [52]. The galactose 
residue of the α1,6 branch was shown to experience slightly less motion when 
compared to the α1,3 branch for both mono- and disialylated Fc; however the 
sialic acids were highly dynamic and did not interact strongly with the polypeptide 
backbone. This data supports hypersialylated and disialylated crystal structures 
where the terminal sialic acid modeled on the α1,6 arm projects away from the 
protein backbone [53, 54].  
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ABSTRACT 
 
Immunoglobulin G (IgG) is a central mediator of host defense due to its ability to 
recognize and eliminate pathogens. The recognition and effector responses are 
encoded on distinct regions of IgGs. The diversity of the antigen recognition Fab 
domains accounts for IgG’s ability to bind with high specificity to essentially any 
antigen. Recent studies have indicated that the Fc effector domain also displays 
considerable heterogeneity, accounting for its complex effector functions of 
inflammation, modulation and immune suppression. Therapeutic anti-tumor 
antibodies, for example, require the pro-inflammatory properties of the IgG Fc to 
eliminate tumor cells, while the anti-inflammatory activity of intravenous 
immunoglobulin G (IVIG) requires specific Fc glycans for activity. In particular, the 
anti-inflammatory activity of IVIG is ascribed to a small population of IgGs in which 
the Asn297-linked complex N-glycans attached to each Fc CH2 domain include 
terminal a2,6-linked sialic acids. We used chemoenzymatic glycoengineering to 
prepare fully di-sialylated IgG Fc and solved its crystal structure. Comparison of 
the structures of asialylated Fc, sialylated Fc, and F241A Fc, a mutant that 
displays increased glycan sialylation, suggests that increased conformational 
flexibility of the CH2 domain is associated with the switch from pro- to anti-
inflammatory activity of the Fc. 
 
KEYWORDS 
 
sialylated IgG Fc, inflammation, IVIG, N-linked glycan, X-ray crystallography   
  
18 
INTRODUCTION 
IVIG is used worldwide as an antibody replacement therapy and as a treatment for 
a variety of inflammatory disorders [55]. IVIG is pooled IgG from the serum of 
healthy donors. It contains the four different subtypes of human IgG (IgG1, IgG2, 
IgG3, and IgG4) and over 30 glycovariants [9]. Although the beneficial effects of 
IVIG as an anti-inflammatory preparation are apparent, the mechanism of action 
has only recently begun to be understood as being correlated with the relatively 
constant portion, or Fc region, of IgGs [56]. The Fc region of IgG interacts with a 
variety of receptors, determined by the amino acid and glycan composition of the 
Fc. Among these receptors are the canonical FcγRs: four are activating (FcγRI, 
FcγRIIA, FcγRIIIA, FcγRIIIB) and one is an inhibitory receptor (FcγRIIB) [56]. The 
simultaneous expression of these receptors on effector cells sets a threshold for 
inflammatory responses [57]. IVIG causes an up-regulation of the inhibitory 
receptor FcγRIIB, initiating anti-inflammatory responses [58]. 
 
A downside of IVIG therapy is that it is only effective when administered at 
high doses (1-3 g/kg) when treating inflammatory diseases [59]. Rationalizing the 
high dose requirements, the anti-inflammatory activity of IVIG has been attributed 
to a small population of IgGs with α2,6-sialyated N-linked glycans attached to a 
conserved asparagine (Asn297) in the Fc CH2 domain [44]. The Asn297-linked 
carbohydrate is a complex, usually core-fucosylated, biantennary glycan 
containing a pentasaccharide Man3GlcNAc2 core (Man, mannose; GlcNAc, N-
acetylglucosamine), which can be modified by addition of terminal galactose or 
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sialic acid [8] (Fig. 1).  Approximately 10% of the Fc regions in IVIG terminate in 
sialic acid, of which 1-3% are disialylated [7, 43]. In vivo studies have shown that 
Fc sialylation is the main determinant in IVIG anti-inflammatory activity [43, 60]. 
For example, IVIG that was enriched in terminally-sialylated Fc glycans showed a 
10-fold increase in anti-inflammatory activity [44, 46], and if IVIG was treated with 
neuraminidase to remove terminal sialic acids or with PNGase F to remove the 
entire N-linked glycan, the anti-inflammatory activity of IVIG was abrogated [43]. 
Similar results were found for recombinant, 2,6 sialylated IgG1 [44]. In mouse 
models, including a serum-induced arthritis model in mice, sialylated Fc (sFc; 
defined here as referring to a mixture of sialylated glycoforms) decreased 
inflammation of ankle joints [43], and IVIG activity was shown to be dependent 
upon terminally-sialylated Fc regions in four independent in vivo model systems of 
autoimmune disease mediated by auto-antibodies [60]. 
 
The anti-inflammatory properties of sFc have been attributed to the effect of 
sialylation switching the specificity of Fc binding to its receptors. In vivo 
experiments showed that the anti-inflammatory effects of sFc required expression 
of the C-type lectin-like receptor-specific intracellular adhesion molecule-grabbing 
non-integrin R1 (SIGN-RI) (the mouse homolog of human dendritic cell-specific 
intercellular adhesion molecule-3-grabbing nonintegrin; DC-SIGN), leading to a 
model in which conformational changes in Fc resulting from sialylation of the 
Asn297-attached glycan allowed interactions with members of the SIGN receptor 
family [61]. Indeed, previous structural studies demonstrated that modification of 
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the Asp297-linked glycan could affect Fc structure. For example, it was shown that 
the glycan contributed to an “open” conformation of IgG Fcs, in which the CH2 
domains were separated by a larger distance than in deglycosylated Fc structures 
[5]. If the IgG Fc glycan was enzymatically removed, the CH2 region adopted a 
“closed” state [62]. Conformational changes have also been observed when 
individual sugar residues on the Fc-linked glycan were modified. When fucose was 
removed, a subtle change involving Tyr296 was observed in X-ray crystallographic 
and NMR structures [29, 31]. This modification resulted in an increased affinity for 
the activating receptor FcgRIIIa, leading to enhanced antibody-dependent cellular 
cytotoxicity (ADCC) activity [27, 32]. Solution NMR studies have reported 
increased mobility of the glycan arms upon sialylation, further supporting the 
contention that alterations in the glycan composition can influence the structure of 
the Fc [52]. 
 
Here we solved the crystal structure of a chemically-homogeneous 
disialylated Fc (di-sFc) and compared it to new structures of a partially sialylated 
Fc (F241A Fc) and wtFc, as well as to wtFc and glycomutant Fc structures 
available in the protein data bank (PDB). We found that di-sFc and F241A Fc show 
increased conformational heterogeneity in crystals compared to wtFc, a 
characteristic that may relate to sialylation and anti-inflammatory properties. 
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RESULTS 
Glycan Analysis of Purified Fc Proteins 
Proteins were produced by transient transfection in HEK 293-6E cells as IgG1 Fc 
fragments (wtFc, F241A Fc and F243A Fc) or in a stably-transfected Chinese 
hamster ovary (CHO) cell line (wtFc) [63]. Disialylated sFc (di-sFc) was prepared 
by chemoenzymatic glycoengineering [64] of an Fc fragment isolated after papain 
cleavage of Rituximab, a human IgG1.  
 
Carbohydrate analyses of N-glycans released from the Fc proteins revealed 
that the N-glycans attached to Asn297 of wtFc expressed in either HEK293 or 
CHO cells consisted of only three glycoforms: G0F, G1F, and G2F (Fig. 2a,b,). 
This result was consistent with previous studies investigating glycoforms of IgGs 
expressed in HEK cells [65]. Neither mono- nor disialylated N-glycans on either 
form of wtFc were detected. By contrast, the glycans attached to the F241A and 
F243A Fc mutants contained more diverse glycoforms: in addition to the G0F, 
G1F, and G2F glycoforms, significant portions of the N-glycans carried a bisecting 
GlcNAc moiety and contained terminal sialic acids (Fig. 2c,d,). The sialylated forms 
included about 20% of terminally monosialylated N-glycans (S1G2F and other 
monosialylated glycoforms) and about 4% of disialylated N-glycans (S2G2F and 
other disialylated glycoforms). These results were consistent with a recent study of 
the F241A and F243A Fc mutants [65], suggesting that these substitutions 
promote further processing of Fc glycans resulting in generation of sialylated and 
bisecting GlcNAc-containing glycoforms. The chemoenzymatically remodeled Fc 
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(di-sFc) was almost homogeneous: >95% of the N-glycans were the disialylated 
glycoform (Fig. 2e, Fig. S1). 
 
 We also compared the Fc proteins in a Western blot using Sambucus Nigra (SNA), 
 a lectin that binds preferentially to α2,6-linked sialic acid attached to a terminal 
galactose [45]. As expected, SNA blots of wtFc, F241A, F243A and di-sFc proteins 
demonstrated sialylation of di-sFc, F241A Fc and F243A Fc, but not wtFc (Fig. 3). 
These results were consistent with previous reports of partial sialylation of the N-
glycans of F241A and F243A Fc [66]. 
 
Liquid chromatography/electrospray ionization mass spectrometry (LC-ESI-
MS) was used to analyze wtFc that was expressed as an Fc fragment in HEK cells 
before and after complete removal of the N-glycans by PNGase F treatment. The 
analysis revealed two major species that were 950 and 1315 Da larger than the 
calculated molecular mass of the polypeptide backbone following PNGase F 
treatment, suggesting the existence of additional posttranslational modifications 
(Fig. S2a). A similar analysis of wtFc expressed in CHO cells revealed three major 
species that were 269, 922, and 1218 Da larger than the calculated molecular 
mass of the polypeptide backbone (Fig. S2b). The results for the F241A Fc and 
F243A Fc proteins that were expressed in HEK cells were the same as the HEK-
expressed wtFc (Fig. S2c,d). In contrast, an Fc fragment prepared from papain 
cleavage of an intact IgG1 (Rituximab) did not contain posttranslational 
modifications other than the N-glycans (Fig. S2e). A monosaccharide composition 
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analysis of the recombinant Fcs after removal of the N-glycans with PNGase F 
revealed the presence of GalNAc, GlcNAc, Gal, and Neu5Ac (Fig. S3b,c), 
suggesting the existence of O-linked glycans. In contrast, the Fc fragment 
prepared from papain cleavage of Rituximab did not contain any monosaccharides 
after PNGase F cleavage (Fig. S3d). On the basis of the additional molecular 
mass (950 Da) in comparison with the polypeptide backbone, the major O-glycan 
on the HEK-expressed Fcs appeared to be a core 1 structure carrying two sialic 
acid residues [calculated mass for (Neu5Ac)2-Gal-GalNAc–H2O = 947.86 Da]. In 
the CHO-expressed wtFc, an additional mass of 1218 Da on the polypeptide 
backbone was observed. However, this additional mass does not correspond to 
typical O-glycan structures, implicating potential additional modifications to the 
core structures; e.g., acetylation on the sialic acid moieties. The detailed structures 
of the O-glycans remain to be determined. However, the lack of reactivity of HEK-
expressed wtFc in the SNA blot (Fig. 3) demonstrated that there were no α2,6-
linked sialic acids on the putative O-glycans. Since the hinge region of IgG where 
the O-glycans would likely be located is usually disordered in Fc crystal structures, 
these glycans (if present) would not be visible in published structures of 
recombinantly-expressed Fc fragments [38, 65, 67, 68]. Nor are there apparent 
differences in the structural properties of Fcs that correlate with whether they were 
expressed as Fc fragments versus prepared by cleavage of intact IgG (Table 1).  
The finding of putative O-glycans on proteins expressed as Fc fragments, 
but not on an Fc fragment derived by cleavage of intact IgG, could be explained if 
expression of Fc as a fragment allows access during biosynthesis by O-glycan-
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adding enzymes in the Golgi apparatus to a region of the IgG hinge that is 
inaccessible when intact IgG is trafficking through the Golgi. Although there were 
no apparent structural differences in Fcs as a function of whether or not they were 
produced in a form predicted to contain the putative O-glycan, these results 
suggest that functional studies employing Fcs expressed directly as fragments 
should compare results with Fcs derived by enzymatic cleavage of intact IgGs to 
rule out potential effects of unnatural O-glycosylation.  
 
wtFc Structures Are Relatively Similar  
In order to assess potential conformational differences in Fc structures, we first 
compared wtFc structures available in the Protein Data Bank (PDB) and a 2.4 Å 
resolution wtFc structure solved in this study (space group P212121; one molecule 
per asymmetric unit) (Supplementary Table 1). We defined “wild type” as those Fc 
structures that were derived from IgGs or Fc fragments containing the naturally-
occurring mixture of N-glycans attached to Asn297 when the protein was produced 
in mammalian cells, which included our new wtFc structure and PDB entries 1H3X, 
3AVE, 2DTS, 3DO3, 1FC1, and 1HZH. Fc fragments are homodimers in which the 
N-terminal CH2 domains contact each other through their Asn297-linked N-
glycans, and the C-terminal CH3 domains form a stable interface that is relatively 
constant between structures (Fig. 1b and 4a). Although the CH2 domain N-glycans 
are generally heterogeneous in wtFc proteins (Fig. 2), ordered electron density is 
usually observed for eight or nine carbohydrate residues of the biantennary 
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complex glycan attached to the Asn297 of each CH2 domain (PDB codes: 1H3X, 
3AVE, 2DTS, 3DO3, 1FC1, and 1HZH).  
In order to evaluate potential differences in wtFc and sialylated Fc 
structures (Fig. 4), the CH3 domains of the wtFc structures were aligned, and we 
monitored the separation of the CH2 domains as previously described [69] by 
measuring distances between the Ca atoms at CH2 positions 238, 241, 301, and 
329. The differences in CH2 domain separation (Table 1) relative to a published 
wtFc structure (3AVE) were plotted for each set of paired Ca positions (Fig. 5). 
Despite differences in crystal packing, the wtFc structures exhibited only small 
deviations in CH2 domain separation distances, demonstrating relatively little 
structural variability. By contrast, a low-resolution wtFc structure solved from 
crystals grown under high salt conditions [5] (PDB: 1H3Y) showed deviations from 
other wtFc structures that were crystallized in lower salt concentrations (Fig. 5, 
Table 1). Structures of Fc proteins with different defined glycoforms showed a 
larger degree of variability in CH2 domain separation than wtFc structures, as was 
also true for Fc structures with mutations introduced to enhance effector functions, 
and Fc structures solved as complexes with other proteins (Fig. 5). There were no 
systematic differences in CH2 domain separation or structure based on whether or 
not the Fc fragment was predicted to contain an O-glycan in its hinge region (Table 
1; Fig. 5).  
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Structures of Two Forms of di-sFc  
A 3.0 Å resolution of di-sFc was solved in space group P21 with two di-sFc 
molecules per asymmetric unit. The structure was compared with wtFc structures 
and a previously described structure of sFc that included a mixture of di- and 
monosialylated Fc (PDB: 4BYH) [53]. In the di-sFc structure, electron density for 
biantennary N-linked glycans was visible for all four di-sFc chains in the two di-sFc 
dimers, but although the di-sFc protein was fully disialylated (Fig. 2e), electron 
density for a terminal sialic acid was found only on the 6-arm of chains B and C, 
with the 6-arm of chains A and D showing ordered glycan residues up to a GlcNAc 
or galactose, respectively, and the 3-arm showing electron density for glycan 
moieties up to the GlcNAc (chains A, B, C and D) (Fig. 6). Similarly, sialic acid was 
visible only on the 6-arm of chain A in the 4BYH sFc structure [53]. In all three sFc 
structures (in 4BYH as well as in the two copies of di-sFc in the new sFc structure), 
the 6- and 3-arms of the biantennary glycans projected away from the protein 
surface and were solvent exposed; thus the ordered sialic acid on the glycan 6-
arm was not positioned into a pocket formed by Glu258 and Lys290, as previously 
proposed [61]. 
 Interestingly, the two di-sFc dimers in the asymmetric unit of the P21 
crystals exhibited differences in the arrangement of their CH2 domains. One di-sFc 
(chains A and B) exhibited a relatively “closed” conformation, as defined by the 
separation between the two CH2 domains, whereas the second di-sFc (chains C 
and D) exhibited a relatively “open” conformation (Table 1 and Fig. 4b). As 
compared with a representative wtFc structure (3AVE), the open di-sFc exhibited a 
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6.8 Å root mean square deviation (RMSD) (calculated for the 103 Cα atoms of one 
CH2 domain after alignment of the partner CH2 domain in each structure), as 
compared to a 15.0 Å RMSD between the wtFc and closed di-sFc CH2 domains, a 
7.9 Å RMSD between the open di-sFc and the 4BYH sFc, and a 8.8 Å RMSD 
between the closed di-sFc and the 4BYH sFc. To quantitatively evaluate CH2-CH2 
domain separation distances, which cannot be easily defined by a single number 
reflecting an average separation, we used a previously-defined metric in which the 
distance between four partner Cα atoms on each CH2 domain are measured 
(Pro238, Pro329, Phe241 and Arg301) and compared between structures [69]. In 
addition to determining CH2-CH2 separation distances for these Cα residues (Table 
1), we calculated the differences relative to a reference wtFc structure (3AVE) to 
determine how greatly the various structures deviated from wtFc and other Fc 
structures. As defined by the distances between these Cα atoms, the closed di-
sFc exhibited a greater difference in CH2 domain separation when compared to 
wtFc structures than 4BHY sFc, whereas the open di-sFc Cα exhibited a 
difference within the range observed for other wtFc structures (Fig. 5).  
 We next aligned individual CH2 domains of the closed di-sFc, open di-sFc, 
wtFc (3AVE), and 4BYH sFc structures to compare the orientations of hydrophobic 
side chains (Phe241 and Phe243) adjacent to the N-linked glycan attached to 
Asn297 (Fig. 7a). No major changes were observed in the overall fold of the CH2 
domains, and only minor changes were found in the Phe243 side chain orientation. 
However, larger changes were observed in the Phe241 side chain, which was 
rotated ~90° compared to Phe241 in other Fc structures (Fig. 7b). Typically the 
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aromatic rings of the Phe241 and Phe243 side chains were stacked with respect to 
each other; however in both CH2 domains of the closed and open di-sFc 
structures, Phe241 adopted a different conformation such that it was no longer 
stacked with Phe243 (Fig. 7b,c and Fig. S4). The Phe241 side chain was not 
involved in crystal contacts in any of the structures (data not shown); thus these 
differences were not related to crystal packing. Although the Asn297-linked N-
glycan is adjacent to Phe241 and Phe243, no major differences were observed in 
the glycan conformation (Fig. 7a), thus the Phe241 side chain orientation did not 
affect the glycan conformation.  
 
Structure of F241A Fc 
We also solved a 2.2 Å resolution crystal structure of F241A Fc (space group 
P212121; one molecule per asymmetric unit) and compared it to wtFc and sFc 
structures and to PDB code 4BM7, a previous F241A Fc structure [65] (Fig. 8a, b). 
On chain A of the new F241A Fc structure, there was ordered electron density for 
residues Pro230 to Leu443, which included part of the hinge region (Glu216 to 
Pro230 for human IgG1 proteins) that normally links the Fab to the N-terminus of 
the Fc region (Fig. 8c). By contrast, the first ordered residue on both chains of 
wtFc structures was usually Leu234, Leu235, Gly236, Gly237, or Pro238 (PDB 
codes: 1H3X, 3AVE, 2DTS, 3DO3, 1FC1 and 1HZH), and the first ordered residue 
of the F241A B chain was Gly237. The hinge region was also disordered in the 
4BM7 F241A Fc structure (the first ordered residues were Gly237 on chain A and 
Pro238 on chain B). At Asn297, six ordered glycan residues were modeled on 
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chain A and nine residues on chain B of the new F241A structure (Fig. 6), but sialic 
acids were not visible in the new F241A or the 4BM7 F241A structures although 
the F241A glycans included both mono- and disialylated species [65] (Fig. 2 and 
Fig. 8b). Because N-glycans were not completely resolved even in the di-sFc 
structure, which was solved from crystals containing Fc protein with completely 
homogeneous N-glycans, we cannot use the F241A Fc structures to determine the 
compositions of N-glycans in the F241A Fc crystals. Therefore it is not possible to 
determine whether a defined glycan species crystallized from the heterogeneous 
protein preparations used to produce both of the F241A Fc structures and all of the 
wtFc structures.  
 Comparison of the CH2 domain separations of the F241A Fc structure with 
other Fc structures showed that the new F241A Fc structure was similar to wtFc 
structures and the open di-sFc structure, but substantially more closed than the 
4BM7 F241A Fc (Fig. 5, Table 1). (Because portions of the chain B CH2 domain of 
the 4BM7 F241A Fc structure were disordered, including the Asn297-linked glycan 
and residues 264-274 (BC loop), 296-300 (C’E loop), and 324-332 (FG loop), we 
could not measure all of the inter-chain distances in the 4BM7 F241A Fc 
structure.) This large degree of difference in F241A Fc conformations is similar to 
that observed for di-sFc conformations but distinct from wtFc conformations. Since 
both of the F241A Fc structures (the structure reported here and the 4BM7 
structure) were derived from proteins that were partially sialylated, this observation 
is consistent with the suggestion that a greater degree of conformational 
heterogeneity is available to sialylated Fc proteins than to wtFc with conventional 
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glycosylation species. Alternatively, or perhaps in addition, the F241A substitution 
itself could result in greater conformational heterogeneity.  
 
DISCUSSION 
The Fc regions of IgGs can function to either promote or suppress the 
inflammatory response. Previous studies have shown that the Asn297-linked N-
glycan composition is a determining factor in function [46, 70]. Both biochemical 
and in vivo studies have shown that sialylation of the Fc glycan is essential for the 
anti-inflammatory activity of IVIG [9, 43, 46]. Here we compared structures of wtFc, 
which carries mostly asialylated N-glycans, to sialylated forms of Fc, both a fully 
disialylated form produced by chemoenzymatic glycoengineering, and an F241A 
mutant form of Fc. Compared with wtFc, the Asn297-linked N-glycan of F241A and 
F243A Fc showed increased mono- and disialylated products when the protein 
was expressed in mammalian cells. This suggests that IgGs with an F241A 
mutation may be effective anti-inflammatory molecules due to increased 
sialylation.  
Our analyses of the wtFc proteins produced in two different mammalian cell 
lines demonstrated that the Asn297-linked N-glycans were mainly G0F, G1F and 
G2F glycoforms, consistent with previous studies [65], thus we assume a similar 
composition for the N-glycans on the relatively structurally-invariant wtFc 
structures in the pdb. Not only are these glycans mostly asialylated, they also 
contain only a small percentage of digalactosylated forms. In a systematic 
comparison of wtFc structures reported here and previously, we found only small 
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deviations in the “openness” of the Fc, evaluated by the distance between the 
partner CH2 domains in the Fc dimer, despite different crystal packing 
environments: however, we noted that certain glycan species cause increased 
variation in crystal structures. For example, the F241A Fc structure reported here 
and one described previously [65] showed a larger degree of variation in CH2 
domain orientations than seen in a survey of seven wtFc structures. Other 
glycovariants of Fc, including a recent structure of a digalactosylated form of wtFc 
[71], also showed a larger degree of conformational variability as assessed by 
differential CH2 domain separations.  
Similar to the partially sialylated F241A Fc structures, crystal structures of 
sialylated wtFc (sFc) have been found in several conformations. In our crystal 
structure of fully disialylated Fc, we found both open and closed CH2 domain 
conformations in the same crystal, and a previously published sFc structure [53] 
revealed a conformation similar to the canonical wtFc structures, again suggesting 
a large degree of inter-domain flexibility of sialylated forms of Fc compared to the 
relatively invariant structures of asialylated wtFc.  
Recent molecular dynamics simulations showed a wide range of 
conformations that Fc can adopt [71]. Here we have documented a greater 
flexibility of glycovariant forms of Fc that may be key to the ability of the Fc region 
of IgG to modulate inflammatory and anti-inflammatory activities mediated by 
glycan differences. Further structural investigations of how glycan composition and 
conformational flexibility affect binding to Fc receptors that mediate differential 
activities will be critical to understanding the significance of these results.  
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FIGURE LEGENDS 
Fig. 1. IgG, Fc and glycan structures. (a) Schematic structure of IgG1. (b) Ribbon 
diagram of wtFc (PDB: 3AVE) with Asn297-linked N-glycans shown as sticks. 
Glycan residues are colored as in panel c. (c) Schematic of an Asn297-linked N-
glycan. The biantennary glycan consists of a mannose (Man) and N-
acetylglucosamine (GlcNAc) core that can be modified by addition of core 
fucosylation (Fuc), a bisecting GlcNAc, terminal galactose (Gal) and sialic acid 
(NeuNAc).  
 
Fig. 2. HPAEC-PAD analysis of PNGase F-released N-glycans of IgG Fc proteins. 
(a) wtFc expressed in HEK cells. (b) wtFc expressed in CHO cells. (c) F241A Fc 
expressed in HEK cells. (d) F243A expressed in HEK cells. (e) di-sFc prepared by 
chemoenzymatic glycoengineering of an Fc fragment isolated after papain 
cleavage of Rituximab. The amounts of mono- and disialylated N-glycans are 
shown. * indicates a mixture of heterogeneous monosialylated glycoforms. † 
indicates a mixture of heterogeneous disialylated glycoforms. ‡ indicates a satellite 
peak due to epimerization of reducing end GlcNAc to ManNAc. 
 
Fig. 3. SDS-PAGE (left) and SNA blot (right) of Fc proteins expressed in HEK 
cells. wtFc, F241A Fc and F243A Fc were expressed as Fc fragments; di-sFc was 
prepared by papain cleavage from Rituximab IgG.  
 
  
33 
Fig. 4. Comparison of wtFc and sFc structures. Fc structures were aligned by 
superimposing the CH3 domains. (a) Alignment of wtFc structures (the wtFc 
structure solved in this study plus PDB entries 1HZH, 1FC1, 2DTS, 3AVE, 1H3X, 
and 3DO3). (b) Alignment of closed and open structures of di-sFc (this study), sFc 
(PDB 4BYH), and wtFc (PDB 3AVE).  
 
Fig. 5. Comparison of CH2 domain separation in Fc structures. Left: location of Cα 
atoms of Phe241, Arg301, and Pro329 (red spheres) and Asn297 (blue spheres) 
indicated on the CH2 domains of wtFc (PDB: 3AVE). CH2 domain separation in 
individual Fc structures was evaluated by measuring distances (dotted lines) 
between the corresponding red spheres on each chain. Right: Differences in CH2 
domain separation relative to a reference wtFc structure (3AVE) plotted for each 
set of paired Cα positions in the indicated category of Fc structure. When a 
structure category had more than one member, the mean and standard deviation 
are superimposed upon the values. Fc structure categories are as follows: wtFc 
(structure solved in this study plus PDB entries 1H3X, 3AVE, 2DTS, 3DO3, 1FC1, 
1HZH), wtFc high salt (1H3Y), glycovariant (GV) Fcs (1H3W, 1H3U, 1H3V, 2WAH, 
4ACP, 3DNK, 4KU1, and 3S7G), mutant (mut) Fcs (2QL1, 3FJT, and 3C2S), Fcs 
complexed with other proteins (com Fc) (3D6G, 1L6X, 1OQO, 1OQX, 1DN2, 
1FCC, 1FC2, 1E4K, 1T83, 1T89, 3AY4, 3RY6, 3SGK, and 3SGJ), di-sFc closed, 
di-sFc open, sFc (4BYH), F241A Fc (this study), and F241A Fc (4BM7). 
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Fig. 6. Comparison of ordered glycans on Fc structures. 2Fo-Fc electron density 
(contoured at 0.7σ) from an annealed omit map in the region of the Asn297-linked 
N-glycan is shown for both chains of di-sFc closed, di-sFc open, F241A Fc, and 
wtFc (this study). Ordered glycan residues are shown schematically below each 
map using the colors and shapes defined in Fig. 1c.  
 
Fig. 7. Comparison of glycan and protein residue conformations in sFc and wtFc 
structures. (a) Alignment of Asn297-linked N-glycans of di-sFc closed (blue), di-
sFc open (green), F241A Fc (magenta), F241A Fc 4BM7 (yellow), sFc 4BYH 
(cyan), wtFc from this study and wtFc 3AVE (both gray). The side chains of 
Phe241 and Phe243 are shown in red on the CH2 domain of wtFc. (b) Alignment of 
Phe(Ala)241–Leu242–Phe243 region in the structures of di-sFc closed (blue), di-
sFc open (green), F241A Fc (magenta), F241A Fc 4BM7 (yellow), sFc 4BYH 
(cyan), wtFc from this study and wtFc 3AVE (both gray). (c) 2Fo-Fc electron 
density (contoured at 0.7σ) from an annealed omit map in the region of the 
Phe241 and Phe243 side chains for the di-sFc structures. See also Fig. S5. 
 
Fig. 8. Comparison of F241A Fc structures. (a) Superimposition of 
Ca traces of F241A Fc (this study) (magenta) and F241A Fc (PDB 4BM7) (cyan).  
Locations of Ca traces of F241A Fc (this study) (magenta) and F241A Fc (PDB 4B
M7). (b) 2Fo-Fc electron density (contoured at 0.7σ) from annealed omit maps for 
F241A Fc (this study) and F241A Fc (PDB: 4BM7). Ordered glycan residues are 
shown schematically below each map using the colors and shapes defined in Fig. 
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1c. (c) 2Fo-Fc electron density (annealed omit map) of an ordered portion of the 
hinge region (blue) on chain A contoured at 0.6σ. (d) 2Fo-Fc electron density 
(contoured at 0.7σ) from annealed omit maps in the region of the Phe243 and 
Ala241 side chains for the structures of F241A Fc (this study) (left) and F241A Fc 
(PDB: 4BM7) (right). 
 
Fig. S1. LC-ESI-MS analysis of reduced Rituximab Fc. (a) Reduced Rituximab Fc 
treated with wild type EndoS (calculated MW = 25289 Da). (b) Reduced di-sFc 
produced from Rituximab Fc (transglycosylated product) treated with wild type 
EndoS (calculated MW = 27288 Da). 
 
Fig. S2. LC-ESI-MS analysis of reduced recombinant Fc fragments before (left 
panels) and after (right panels) PNGase F treatment to completely remove N-
glycans. ESI-MS spectra after deconvolution are shown for (a) wtFc (HEK cells) 
[calculated MW after PNGase F treatment = 25838 Da; experimentally found MW 
= 26788 and 27153 Da (+950 and +1315 Da, respectively)]; (b) wtFc (CHO cells) 
[calculated MW after PNGase F treatment = 25337 Da; experimentally found MW 
= 25606, 26259, and 26555 Da (+269, +922, and +1218 Da, respectively)]; (c) 
F241A Fc (HEK cells) [calculated MW after PNGase F treatment = 25762 Da; 
experimentally found MW = 26713 and 27077 Da (+951 and +1315 Da, 
respectively)]; (d) F243A Fc (HEK cells) [calculated MW after PNGase F treatment 
= 25762 Da; experimentally found MW = 26713 and 27077 Da (+951 and +1315 
Da, respectively)]; (e) wtFc fragment prepared by papain digestion of Rituximab 
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IgG [calculated MW after PNGase F treatment = 24938 Da; experimentally found 
MW = 24938 Da]. 
 
Fig. S3. HPAEC-PAD neutral monosaccharide compositional analyses of putative 
O-glycans. Left panels: neutral monosaccharide compositional analyses. Right 
panels: sialic acid compositional analyses. (a) Monosaccharide standards. (b) 
Analytes from wtFc expressed in HEK cells after complete removal of N-glycans. 
(c) Analytes from wtFc expressed in CHO cells after complete removal of N-
glycans. (d) Analytes from Fc fragment isolated after papain digest of Rituximab. 
 
Fig. S4. Comparison of glycan and protein residue conformations in sFc and wtFc 
structures (see also Fig. 7). (a) Glycan conformation in the vicinity of the Phe241 
and Phe243 residues (highlighted in red). Glycan residues are colored as in Fig. 
1c. (b) Schematic structures of ordered glycan residues using the colors and 
shapes defined in Fig. 1c. (c) 2Fo-Fc electron density (contoured at 0.7σ) from 
annealed omit maps in the region of the Phe243 and Phe241 side chains for the 
indicated structures.  
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METHODS 
Protein Expression and Purification 
 Fc proteins were expressed in transiently-transfected HEK 293-6E 
suspension cells (F241A Fc and F243A Fc) or stably-transfected Chinese hamster 
ovary cells (wtFc) as described [63, 72]. Fc proteins were isolated from harvested 
supernatants using protein A chromatography (GE Healthcare) followed by size 
exclusion chromatography in 25 mM Tris-Cl pH 7.5, 100 mM NaCl on a Superdex 
16/60 gel-filtration column (GE Healthcare). Fractions corresponding to the Fc 
were pooled and used for crystallization and glycan analysis.  
 Fc protein for di-sFc production was prepared by papain cleavage of 
Rituximab (Rituxan®) (Genentech, Inc., California), a human IgG1 Fc. Rituximab 
(40 mg) was buffer exchanged into 10 mM Tris-HCl pH 7.5 overnight at 4ºC. 
Dialyzed material was concentrated to 20 mg/ mL (~2 mL). Immobilized papain 
(Thermo Scientific) was prepared following the manufacturer’s protocol. 1 mL of 
immobilized papain slurry (50% immobilized papain) was added to the Rituximab 
solution. The reaction was incubated at 37ºC for 5 hours while continuously 
inverting the sample tube. The resin was removed using a spin column and the 
filtrate was loaded over a protein A column (2 x 5 mL) that was pre-equilibrated 
with 10 mM Tris-HCl, pH 7.5. The column was washed with 10 column volumes of 
10 mM Tris-HCl, pH 7.5 until no protein was detected in the flow through. Bound 
Fc was eluted in 4 mL of a 100 mM citric acid solution pH 3.5. Eluted fractions 
were quickly neutralized using a 1.5 M solution of Tris-HCl pH 8.8. Purified Fc was 
combined, concentrated and injected over a 40 mL (4 x 10 mL) HiTrap desalting 
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column (GE Healthcare) pre-equilibrated in a phosphate buffered saline solution 
(pH 7.4) to give 10 mg of Fc. wtFc for crystallization was prepared similarly by 
papain digestion of the anti-HIV-1 IgG1 antibody 21c (expressed in HEK 293-6E 
cells as described [72]).  
 
Preparation of Disialylated Fc (di-sFc) 
Purified Fc (10 mg) prepared by papain cleavage of Rituximab IgG was treated 
with 30 µg of recombinant S. pyogenes EndoS [64] for 1 hr at 37ºC. Analysis by 
LC-MS showed complete cleavage of the glycan. The deglycosylated Fc was 
isolated using a Sephacryl S-200 HR size exclusion column (GE Healthcare) while 
monitoring UV absorbance and collecting peaks. The fractions containing 
deglycosylated Fc were pooled and concentrated to give 9 mg of the intermediate 
(Fucα1,6)GlcNAc-Fc. A solution of (Fucα1,6)GlcNAc-Fc (5 mg) and sialoglycan-
oxazoline (5 mg) buffered with Tris-HCl (100 mM, pH 7.0, 0.5 mL) was incubated 
with EndoS-D233A (200 µg) [64] at 30ºC. Aliquots were taken at time intervals for 
LC-MS analysis of reaction progression. Quantitative conversion was achieved in 
2 hours. The product was purified using size exclusion chromatography as 
described above. Product fractions were pooled and concentrated to give di-sFc 
(4.5 mg). LC-MS data: calculated for (Fucα1,6)GlcNAc-Fc monomer, MW = 
25287.3 Da; found MW = 25289 Da (deconvolution data obtained from the original 
spectrum). Calculated for fully sialylated N-glycan-Fc monomer, MW = 27288.9 
Da; found MW = 27289 Da (deconvolution data). 
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N-glycan Analysis 
25 µg of each Fc fragment was treated with PNGase F (NEB) in a G7 buffer 
(0.5 M sodium phosphate, pH 7.5) following the manufacturer’s instructions. 
Samples were purified over a CarboPac PGC column and analyzed using HPAEC-
PAD on a Dionex ICS 5000 with a CarboPac PA200 column. The N-glycans were 
eluted in 100 mM NaOH with the following gradient conditions: 0-10 mM NaOAC in 
20 min and then 10-100 mM NaOAc in 20 min. Peaks were assigned using N-
glycan standards purified from PNGase F digestions of Rituximab, sheep IgG 
(Sigma), and sialylglycopeptide (SGP) from chicken egg yolk. 
 
Monosaccharide Compositional Analysis of Putative O-glycans 
 PNGase F-treated Fc proteins lacking N-glycans were dissolved in 3M TFA 
in screw-cap vials. The tubes were sealed and incubated at 100 oC for 4 hours. 
Tubes were then cooled to 25 oC, and the reaction mixture was evaporated to 
dryness in a SpeedVac. The dried samples were dissolved in water and subjected 
to HPAEC-PAD analysis on a CarboPac PA10 column. Monosaccharides were 
eluted with 18 mM NaOH and detected with pulsed amperic detection with a gold 
electrode using a standard monosaccharide waveform. For analysis of sialic acids 
from putative O-glycans, the de-N-glycosylated Fc proteins were treated with 
neuraminidase (NEB) for 16 hours in the desialylation buffer provided by the 
manufacturer (NEB). The samples were then subjected to HPAEC-PAD analysis 
on a CarboPac PA10 column using a sialic acid standard (Sigma) for detection 
and quantification.  
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LC-ESI-MS Analysis of Fc Fragments 
Fc fragments and PNGase F-treated Fc fragments were reduced with 50 mM 
TCEP at 37 °C for 15 minutes and subjected to LC-ESI-MS analysis on an Agilent 
C8 column eluted with a gradient of 0-60% acetonitrile in 10 min.  
 
Crystallization and Data Collection 
 Crystals of di-sFc (space group P21; a = 52.73 Å, b = 154.22 Å, c = 66.12 Å, 
b = 110.78û; two Fc dimers per asymmetric unit) were grown in sitting drop vapor 
diffusion by mixing equal volumes of di-sFc (6.15 mg/ml) with a solution containing 
0.2 M magnesium chloride, 0.1 M sodium acetate pH 5, and 20% (w/v) PEG 6000 
at 20°C. Crystals were cryopreserved in well solution supplemented with 30% 
glycerol. Data were collected to 3.0 Å resolution at beamline 8.2.1 of the Advanced 
Light Source (ALS) at Lawrence Berkeley National Laboratory (LBNL).  
 Crystals of wtFc (space group P212121; a = 49.56 Å, b = 79.69 Å, c = 138.06 
Å; one Fc dimer per asymmetric unit) were grown in sitting drop vapor diffusion by 
mixing equal volumes of protein with a solution containing 0.1 M sodium 
cacodylate pH 6.5 and 18% (w/v) PEG 3350 at 20°C. The protein solution 
contained mainly 21c Fab produced by papain digestion of 21c IgG, but 
contaminating amounts of the Fc crystallized. The Fc crystals were cryopreserved 
in well solution containing 30% glycerol. F241A Fc crystals (space group P212121; 
a = 57.91 Å, b = 74.70 Å, c = 113.71 Å; one Fc dimer per asymmetric unit) were 
grown in hanging drops by mixing F241A Fc (4.4 mg/ml) with 30% PEG 1500 at 
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20°C and cryopreserved in well solution containing 25% glycerol. Data were 
collected for both wtFc (2.4 Å resolution) and F241A Fc (2.2 Å resolution) at 
beamline 12-2 of the Stanford Synchrotron Radiation Lightsource (SSRL). 
 
Data Processing and Structure Determination 
 Diffraction data were processed and indexed using iMosflm [73] and 
integrated and scaled using POINTLESS and SCALA [74, 75]. In addition to 
consideringI/sn and completeness of the highest resolution shell, we used the 
 CC1/2 statistic [76] (correlation coefficient between two random halves of the data 
set where CC1/2 > 10%) to determine the high-resolution cutoff for our data. We 
used Phenix [77] to compute CC1/2 values. Structures were solved by molecular 
replacement using PHASER [78] and using published Fc structures as search 
models (PDB 1H3X for F241A Fc and wtFc; 3D03 for di-sFc). Modeling was done 
using COOT [79] using composite omit maps for building glycans and nearby 
protein residues in the CH2 domains. Crystallographic refinement was done using 
the Phenix crystallography package [77] by refining individual B factors for the 
higher resolution structures (F241A Fc and wtFc; 2.2 Å and 2.4 Å resolution, 
respectively). For the lower resolution di-sFc structure (3.0 Å resolution), we 
refined group B factors and used non-crystallographic symmetry (NCS) restraints 
during refinement. Because the CH2 domain orientations differed between the two 
di-sFc molecules in the asymmetric unit, the NCS restraints were applied to 
individual domains (CH2 domain residues Phe240 – Ile336, and residues CH3 
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domain Pro343 – Leu443 on each Fc chain). We used PyMol [80] for superposition 
calculations and molecular representations. 
 The F241A Fc model (Rfree = 23.2%; Rwork = 20.6%) included 421 protein 
residues in the F241A Fc dimer (Pro230 - Leu443 on chain A and Gly237- Leu443 
on chain B), 16 glycan residues (GlcNAc1-Gal6, Fuc12 on chain A and GlcNAc1-
GlcNAc8, Fuc12 on Chain B), and 351 water molecules. No electron density was 
observed for residues Thr225 and Cys226 of the Fc hinge or for Man7-NeuNAc10 
or Gal9-NeuNAc11 in the N-linked glycan of chain A or B, respectively. The wtFc 
model (Rfree = 26.4%; Rwork = 21.1%) included 415 protein residues in the wtFc 
dimer (Pro238-Ser444 on chain A and Gly236-Pro443 on chain B), 13 glycan 
residues (GlcNAc1-GlcNAc5, Man7, GlcNAc8, Fuc12 on both chains A and B), 
and 165 water molecules. No electron density was observed for residues Cys226 
to Pro230 of the Fc hinge or for Gal6, Gal9 or NeuNAc10 on the N-glycan. Side 
chains were disordered for residues 269 and 311 on chain A and 246, 269, 311, 
and 326 on chain B. The di-sFc structure (Rfree = 28.0%; Rwork = 26.0%) included 
two conformationally distinct Fc dimers (chains A and B in the closed dimer and 
chains C and D in the open dimer). The closed di-sFc dimer model included 414 
protein residues (Gly236 - Ser444 and Pro238 - Ser444 on chains A and B, 
respectively) and 16 glycan residues (GlcNAc1- GlcNAc5, Man7, GlcNAc8 on 
chain A and GlcNAc1 - GlcNAc8, NeuNAc11 on chain B). No electron density was 
observed for residues Glu225 to Pro230 of the Fc hinge or for Gal6, Gal9 - 
NeuNAc10 (chain A) or Gal9, NeuNAc11 (chain B) in the N-linked glycan. Side 
chains were disordered for residues 246, 251, 258, 268, 269, 272, 274, 280, 288, 
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292, 294, 295, 296, 301, 307, 317, 326, 340, 355, 360, 365, 386, 410, 414, 416, 
418, and 433 on chain A and 248, 269, 272, 274, 283, 298, 314, 326, 340, 355, 
384, and 386 on chain B.  The open di-sFc dimer model included 410 protein 
residues (residues Pro238 - Leu443 on each Fc chain) and 17 glycan residues 
(GlcNAc1-GlcNAc8, NeuNAc11 on chain C and,GlcNAc1-GlcNAc8 on chain D). 
No electron density was observed for residues Cys226 to Pro230 of the Fc hinge, 
Ala327-Ile332 (chain C), Val264-Asp270 (Chain D) or for Gal9, NeuNAc10 (chain 
C) or Gal9-NeuNAc11 (chain D) in the N-linked glycan. Side chains were 
disordered for residues 242, 246, 268, 269, 270, 272, 274, 285, 288, 290, 293, 
295, 300, 301, 309, 311, 312, 320, 340, 342, 360, 380, 384, 386, 416, 418, 419, 
and 433 on chain C and 248, 263, 272, 276, 286, 288, 290, 295, 301, 302, 323, 
332, 334, 360, 377, 384, 386, and 439 on chain D.  
 
ACCESSION NUMBERS 
Atomic coordinates and structure factors have been deposited in the Protein Data 
Bank with accession codes 4Q7D (wtFc), 4Q6Y (di-sFc), and 4Q74 (F241A Fc).  
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FIGURES 
 
 
Figure 1. IgG, Fc and glycan structures. 
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Figure 2. HPAEC-PAD analysis of PNGase F-released N-glycans of 
IgG Fc proteins. 
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Figure 3. SDS-PAGE (left) and SNA blot (right) of Fc proteins 
expressed in HEK cells. 
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Figure 4. Comparison of wtFc and sFc structures. Fc structures were 
aligned by superimposing the CH3 domains. 
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Figure 5. Comparison of CH2 domain separation in Fc structures. 
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Figure 6. Comparison of ordered glycans on Fc structures.   
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Figure 7. Comparison of glycan and protein residue conformations in 
sFc and wtFc structures. 
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Figure 8. Comparison of F241A Fc structures.   
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Figure S1. LC-ESI-MS analysis of reduced Rituximab Fc. 
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Figure S2. LC-ESI-MS analysis of reduced recombinant Fc fragments 
before (left panels) and after (right panels) PNGase F treatment to 
completely remove N-glycans. 
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Figure S3. HPAEC-PAD neutral monosaccharide compositional 
analyses of putative O-glycans. 
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Figure S4. Comparison of glycan and protein residue conformations in 
sFc and wtFc structures.  
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Supplementary Table 1.  Data collection and refinement statistics 
 
wtFc di-sFc F241A Fc 
Data Collection    
       Space group P2121 21 P21 P2121 21 
       Cell dimensions    
                 a, b, c (Å) 49.52, 79.48, 137.94 52.73, 154.22, 66.12 57.91, 74.70, 113.71 
                    α, β, γ (°) 90.0, 90.0, 90.0 90.0, 110.8, 90.0 90.0, 90.0, 90.0 
       Resolution (Å) 52.09  - 2.35 (2.43 - 2.35) 48.23 - 3.00 (3.11 - 3.00) 35.65 - 2.19 (2.27 - 2.19) 
       Rmerge 0.055 (0.479) 0.060 (0.536) .053 (0.559) 
       Completeness (%) 99.9 (99.8) 97.8 (96.1) 93.6 (75.5) 
       Redundancy 2.0 (2.0) 1.9 (1.9) 1.8 (1.7) 
       I/σI 9.07 (1.89) 11.07(1.75) 9.76 (1.38) 
       CC1/2(%) 99.9 (79.5) 99.2 (88.5) 99.9 (72.9)  
Refinement    
       Resolution (Å) 2.35 3.00 2.19 
       No. reflections 23368 19336  24276 
       Rwork/Rfree .211/.264 .260/.280 .206/.232 
       No. atoms    
                  Protein 3322 6146 3328 
                  Ligand/ion 198 429 195 
                  Water 165 0 351 
       Average B factor 51.70 71.01 33.20 
       rmsd                    
  Bond lengths (Å) .022 0.013 .007 
                    Bond angles (°) 1.85 1.62 1.17 
    
 
Statistics for the highest-resolution shell are shown in parentheses. !
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Structural Characterization of GASDALIE Fc Bound to 
the Activating Fc receptor FcγRIIIa 
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ABSTRACT 
The Immunoglobulin G (IgG) Fc region initiates inflammatory responses such as 
antibody-dependent cell-mediated cytotoxicity (ADCC) through binding to 
activating Fc receptors (FcγRI, FcγRIIa, FcγRIIIa, FcγRIIIb). These receptors are 
expressed on the surface of immune cells including macrophages, dendritic cells, 
and natural killer (NK) cells together with an inhibitory receptor, FcγRIIb, thereby 
setting a threshold for cell activation. The affinity of IgG Fc for binding activating Fc 
receptors depends on IgG subclass and the composition of N-linked glycans 
attached to a conserved asparagine in the Fc CH2 domain. For example, Fc 
regions with afucosylated glycans bind more tightly to activating receptors than 
fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and 
in vitro. Enhanced pro-inflammatory responses have also been seen for Fc regions 
with amino acid mutations. GASDALIE Fc is an Fc mutant 
(G236A/S239D/A330L/I332E) with increased affinity for activating receptors 
FcγRIIIa. We determined the crystal structure of GASDALIE Fc alone and in 
complex with the activating receptor FcγRIIIa to gain insight on potential structural 
changes in Fc and/or enhanced receptor-Fc interactions between GASDALIE Fc 
and FcγRIIIa. The structure of GASDALIE Fc alone was similar to wild-type Fc 
structures. However, we found increased electrostatic interactions in the 
GASDALIE Fc:FcγRIIIa interface compared with other Fc:FcγR structures that 
could contribute to the increased affinity of GASDALIE Fc for FcγRIIIa.  
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INTRODUCTION 
Immunoglobulin G (IgG) plays critical roles in antibody-mediated immune 
responses through specific engagement of both antigens and immune effector 
cells. The fragment crystallizable (Fc) region specifically engages Fc gamma 
receptors (FcγRs), the initial step in effector functions such as antibody-dependent 
cell-mediated cytotoxicity (ADCC) and phagocytosis [7].  In humans there are two 
activating FcγRs that play a key role in ADCC: FcγRIIa and FcγRIIIa. FcγRIIIa is 
expressed primarily on the surface of natural killer (NK) cells, while FcγRIIa is 
commonly found on macrophages and granulocytes [13]. Both are low-affinity 
receptors, therefore activation of cells results only from crosslinking of these 
surface receptors upon engagement of clustered Fc regions in antibody-antigen 
immune complexes (ICs), although this is not the case for FcγRI, a high affinity 
receptor that can activate cells by binding to monomeric IgG [81]. Activation is 
mediated by immunoreceptor tyrosine-based activating motifs (ITAMs) found on 
the receptor-associated γ-chain. Upon engagement of ICs with FcγRs, these motifs 
become phosphorylated leading to a cascade of events that activate the cell to 
destroy an invading pathogen or infected cell [55]. An inhibitory receptor, FcγRIIb, 
is found on B cells, macrophages, neutrophils, and mast cells [15, 18, 22]. 
Immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic tail of 
FcγRIIb mediate suppression of FcγR activation by activating phosphatases that 
reverse the effects of kinases in the ITAM signaling pathway [55]. Co-expression of 
activating and inhibitory receptors sets a threshold for activation of effector cells.  
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 Fc regions are independently-folded, stable regions of IgGs comprising an 
N-terminal hinge (connected to each of two antigen-binding Fab arms) followed by 
two Ig constant domains, CH2 and CH3, on each chain of the Fc homodimer. FcγR 
receptors bind asymmetrically to Fc homodimers with a 1:1 FcγR:Fc stoichiometry 
to a site involving the hinge region and N-terminal portions of the CH2 domains 
[29]. The Fc region includes a heterogeneous N-linked glycan attached to a 
conserved residue, Asn297, in each Fc CH2 domain. The Asn297-linked glycan is 
a complex carbohydrate composed of a mannose (Man) and N-acetylglucosamine 
(GlcNAc) core that is usually fucosylated. The glycan can be additionally modified 
with a terminal galactose or sialic acid. Typically, wild-type (wt) IgG is 
agalactosylated (G0; 35%), mono-galactosylated (G1; 35%), or digalactosylated 
(G2; 16%) and asialylated (S0; 85%), although mono- and disialylated IgG 
represent 11% and 4%, respectively, of IgG in human serum [10]. Modification of 
the N-linked glycan of IgG Fc can alter its function. For example, terminally 
sialylating the glycan switches the Fc from a pro-inflammatory to anti-inflammatory 
molecule [9, 43, 44, 46, 55, 57, 61, 70], which may correlate with increased 
conformational flexibility compared with wtFc regions [54]. Afucosylation of the 
normally core-fucosylated glycan leads to enhanced binding to the activating 
receptor FcγRIIIa, resulting in enhanced ADCC [28, 29, 31] due to increased 
protein-protein and protein-carbohydrate interactions between the Fc and receptor 
[29, 31]. Removing the N-linked glycan leads to a closed Fc conformation that 
exhibits no binding to any FcγR [11, 66]; however, aglycosylated Fc can bind the 
FcRn protection receptor [11], which recognizes the interface between the CH2 and 
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CH3 domains of each Fc chain [12], a site distant from the Asn297-linked N-linked 
glycan. 
  Previous efforts have been made to alter the IgG Fc region to either 
enhance or suppress binding to FcγRs [11, 29, 31, 35, 36, 38, 55, 82, 83]. In a 
2006 study, IgG Fc with mutations S239D/I332E (SDIE) or S239D/A330L/I332E 
(SDALIE) showed enhanced ADCC and 60-fold (SDIE Fc) and 170-fold (SDALIE 
Fc) increased affinity for binding to FcγRIIIa, respectively [35]. SDIE and SDALIE 
Fc also showed increased binding to the inhibitory receptor, FcγRIIb, by 70-fold 
and 40-fold, respectively [35, 38, 84]. The crystal structure of unbound SDALIE Fc 
revealed a more open conformation compared with wtFc structures, but no major 
changes in the FcγR recognition interface [38]. Related Fc mutants also showed 
increased activity and affinity for binding to FcγRs. A single G236A substitution in 
the Fc showed 7-fold enhanced binding to FcγRIIa and enhanced phagocytosis in 
vitro while Fcs with mutations G236A/S239D/I332E (GASDIE) demonstrated 70-
fold enhancement [36]. The G236A substitution alone did not cause enhanced 
binding to FcγRIIb, whereas the GASDIE mutant showed 14-fold enhanced affinity 
for this receptor [36]. A variant of SDALIE Fc, GASDALIE 
(G236A/S239D/A330L/I332E) Fc, which combined the G236A substitution with the 
SDALIE substitutions, showed increased affinity for activating receptors 
FcγRIIa and FcγRIIIa (13- to 20-fold, respectively). Although GASDALIE Fc bound 
to FcγRIIIa with lower affinity than the SDALIE Fc:FcγRIIIa interaction, GASDALIE 
Fc showed only a ~2-fold increase in affinity for the inhibitory receptor FcγRIIb [33, 
85]. Thus unlike SDALIE Fc, GASDALIE Fc did not cause a great increase in 
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affinity to FcγRIIb (40-fold vs. 2-fold) but did produce an enhanced affinity for 
activating FcγRs.  
 In order to determine the mechanism by which the GASDALIE substitutions 
enhance binding to activating FcγRs, we solved crystal structures of GASDALIE Fc 
alone and in complex with FcγRIIIa, comparing the bound and free GASDALIE Fc 
structures to the previously-solved unbound SDALIE Fc structure [38, 84] and 
other Fc structures. We find that the GASDALIE substitutions do not dramatically 
alter the overall Fc conformation; however, the GASDALIE Fc:FcγRIIIa structure 
revealed increased electrostatic interactions at the binding interface that may 
account for its increased affinity for FcγRIIIa. Our solved GASDALIE Fc:FcγRIIIa 
crystal structure and homology model of GASDALIE Fc:FcγRIIb suggested that the 
G236A substitution that distinguishes GASDALIE Fc from SDALIE Fc is localized 
to the FcγRIIIa/FcγRIIb binding site, thereby counteracting the normally enhanced 
binding of the SDALIE mutations for FcγRs, leading to decreased binding affinity to 
activating FcγRs and little to no change in affinity of GASDALIE Fc compared with 
wtFc for the inhibitory receptor.  
 
RESULTS 
 
Structure of GASDALIE Fc Bound to FcγRIIIa 
GASDALIE Fc and the FcγRIIIa ectodomain were expressed and purified in 
transiently-transfected mammalian cells as previously described [63, 72]. In the 
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case of FcγRIIIa expression, three of five potential N-linked glycosylation sites 
were removed by site directed mutagenesis (N38Q, N74Q, N169Q), and N-linked 
glycans at asparagines 45 and 162 were retained due to their effects on protein 
expression and binding affinity, respectively [29, 30] (Fig. 1). The complex 
structure was solved by molecular replacement using an afucosylated Fc:FcγRIIIa 
complex structure (PDB 3SGK) as a search model and refined to 3.1 Å (Rcryst = 
0.27; Rfree = 0.29) (Fig. 2A). The overall quality of the electron density map allowed 
building of N-linked glycans up to a terminal galactose on the 6-arm and up to a 
terminal GlcNAc on the 3-arm of the N-linked glycans of chains A and B of the Fc 
(Fig. 3A). On FcγRIIIa, ordered electron density was observed for a GlcNAc 
attached to N45 and for two GlcNAcs attached to N162 (Fig. 3B). 
 Similar to previous structures of Fc:FcγRIIIa complexes [28, 29, 31], the 
structure revealed an asymmetric 1:1 interaction in which the FcγRIIIa hinge region 
between domain 1 (D1) and domain 2 (D2) together with the receptor D2 loops 
BC, C’E and FG interacted with the lower hinge region of Fc chains A and B and 
the CH2 domain BC, C’E and FG loops (Fig. 2A). The sites of the GASDALIE 
substitutions (positions 236, 239, 330, and 332) were visible in ordered electron 
density on Fc chains A and B (Fig. 3C). On chain A, Asp239 interacted directly 
with the BC loop of FcγRIIIa. Ala236, Leu330, and, Glu332 did not contact the 
receptor (Fig. 2B). On chain B, Fc residue Glu332 was in direct contact with the 
receptor FG loop. Ala236, Asp239, and Leu330 were not at the binding interface 
(Fig. 2C).  
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 In detailed comparisons of the GASDALIE Fc:FcγRIIIa and wtFc:FcγRIIIa 
(PDB 3SGJ) structures, we found electrostatic interactions resulting from one of 
the GASDALIE substitutions, S239D, in which a positively-charged residue, 
Lys120, in the FcγRIIIa BC loop of D2 was positioned in a pocket between Fc 
chain A residues Asp239 and Asp265 (Fig. 2B, left). By comparison, in the 
wtFc:FcγRIIIa complex, residue 239, a serine, formed a hydrogen bond with 
FcγRIIIa Lys120 (Fig. 2B, right). The introduced residues Leu330, and Glu332 (AL 
and IE in GASDALIE) did not play a role in binding at the interface of FcγRIIIa with 
chain A of GASDALIE Fc. Ala236 (the GA substitution in GASDALIE Fc) also did 
not play a role at the binding interface (Fig. 2B, left); however Gly236 in the 
wtFc:FcγRIIIa complex formed a hydrogen bond with His135 of the receptor (Fig. 
2B, right). The difference in binding affinity between SDALIE and GASDALIE 
suggests that the increase in bulkiness resulting from the G236A mutation causes 
unfavorable binding. This may explain the enhanced binding affinity of SDALIE Fc 
to FcγRIIIa (170-fold) when compared to GASDALIE Fc (20-fold); the G236A 
mutation being the only difference between SDALIE and GASDALIE [33, 35]. 
Conversely, the salt bridge formed by Asp239 on Fc chain A (SD substitution in 
GASDALIE Fc and SDALIE Fc) and Lys120 of FcγRIIIa, which is not seen in 
wtFc:FcγRIIIa complex structures, may contribute to the increased affinity of 
GASDALIE Fc to FcγRIIIa.  
 On chain B of GASDALIE Fc, we found new interactions with the 
introduction of the GASDALIE substitutions that may contribute to the enhanced 
affinity for FcγRIIIa of GASDALIE compared to wtFc [33, 84]. Lys161 of FcγRIIIa 
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formed an electrostatic interaction with residue Glu332, the IE substitution in 
GASDALIE Fc, an interaction not seen in wtFc:FcγRIIIa complex structures (Fig. 
2C, left); Ile332 of wtFc did not interact with FcγRIIIa Lys161 (Fig. 2C, right).  
Ala236, the GA substitution in GASDALIE Fc, does not play a role at the binding 
interface; however Gly236 in the wtFc:FcγRIIIa complex formed a hydrogen bond 
with Lys161 of the receptor (Fig. 2C, right). The decrease in hydrogen bonds in the 
region containing the G236A mutation may lead to unfavorable binding of 
GASDALIE Fc to FcγRIIIa, similar to what was seen at the interface of at chain A. 
 Polymorphisms at residue 158 on FcγRIIIA are known to affect binding to 
Fcs: e.g., FcγRIIIAF158 has a lower affinity for wtFc (KD=2.2 x 10-6 M) compared to 
with the affinity of FcγRIIIAV158 (KD=4.1 x 10-7 M) [33]. The GASDALIE Fc complex 
structure was solved with FcγRIIIAF158, whereas the wtFc complex structure was 
solved with FcγRIIIAV158[29]. Ala236 of GASDALIE Fc (the GA substitution in 
GASDALIE Fc) was near FcγRIIIa residue Phe158 (7.3 Å between the Cα atoms 
of Ala236 and Phe158 compared with 4.9 Å between the Cα atoms of Ala236 and 
Val158 in the wtFc:FcγRIIIa structure) (Fig. 4b). This difference in affinity between 
these two polymorphic forms of FcγRIIIa suggests that an increase in bulkiness of 
residue 158 side chain (valine to phenyalanine) results in less favorable binding to 
Fcs. Similarly, the increase in bulkiness resulting from the G236A substitution in 
GASDALIE Fc may lead to unfavorable binding to FcγRIIIa in the region containing 
Phe158. 
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Modeling of interaction of GASDALIE Fc with FcγRIIb 
 To gain understanding of the selectivity of GASDALIE Fc for the activating 
receptor FcγRIIIa over the inhibitory receptor FcγRIIb,  we used homology 
modeling [80] to create a models of GASDALIE Fc:FcγRIIb and wtFc:FcγRIIb 
complexes based on high-resolution structures of FcγRIIb (PDB 2FCB), the 
wtFc:FcγRIIIa complex (PDB 3SGJ) and the GASDALIE Fc:FcγRIIIa complex 
described in this study. The D2 domains of FcγRIIb and FcγRIIIa share structural 
homology (root mean square deviations, rmsds, ranging from 0.5-0.7 Å for 
pairwise combinations) and bind to Fcs with similar orientations, as demonstrated 
by crystal structures and site-directed mutagenesis [11, 86-90] (Fig. 4). 
 To validate the modeling methods, we first constructed a homology model 
of the GASDALIE Fc:FcγRIIIa using the wtFc:FcγRIIIa complex structure (PDB 
3SGJ) as a starting reference. The modeled GASDALIE Fc:FcγRIIIa exhibited a  
1.2 Å rmsd compared with the GASDALIE Fc:FcγRIIIa crystal structure (calculated 
for all Cα atoms) and reproduced the interactions of the GASDALIE substitutions 
with FcγRIIIa.  
 To generate GASDALIE Fc:FcγRIIb homology model, the D2 domain of 
FcγRIIb was aligned with D2 of FcγRIIIa in the GASDALIE Fc:FcγRIIIa complex 
structure. A similar method was used to generate the wtFc:FcγRIIa homology 
model. There were several interactions predicted by GASDALIE Fc:FcγRIIb and 
wtFc:FcγRIIb homology models that gave insight on the difference in affinity of 
GASDALIE Fc vs. wtFc. As described above, the asymmetric binding of FcγRs to 
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two-fold symmetric Fc regions results in different effects of the Fc substitutions on 
the two chains of the Fc homodimer. On chain A, the Ala236, Asp239, Leu330 and 
Glu332 substitutions were not predicted to play a role in binding at the interface of 
FcγRIIb with GASDALIE Fc chain A; in the wtFc:FcγRIIb homology model  Gly236 
is predicted to form a hydrogen bond with Arg131 of the receptor (Fig. 5B).  
 On chain B of the GASDALIE Fc, Asp239 in GASDALIE Fc, the substitution 
in the SD portion of GASDALIE, was predicted to hydrogen bond with Thr158 in 
FcγRIIb (Fig.5C, left). By contrast, there was a serine at site 239 in wtFc predicted 
not to interact with the receptor (Fig.5C, right). Ala236 (the GA substitution in 
GASDALIE) was predicted not to form any interactions with the receptor however; 
if there is a glycine instead of an alanine at this position, as in wtFc, a hydrogen 
bond is predicted to form between Tyr160 of the receptor and Gly236. The G236A 
substitution in the GASDALIE Fc:FcγRIIb complex may decrease the number of 
hydrogen bonds at the interface similar to what is seen in the GASDALIE 
Fc:FcγRIIIa complex  thereby lowering affinity of GASDALIE Fc to both activating 
and inhibitory receptors when compared to SDALIE Fc (missing GA substitution) 
[33, 35, 84].  
 
Conformations of free and receptor-bound GASDALIE Fc 
In order to determine if unbound GASDALIE Fc exhibits conformational changes 
associated with its increased affinity for FcγRIIIa compared with wtFc, we solved 
the crystal structure of GASDALIE Fc alone by molecular replacement to 2.4 Å 
(Rcryst = 0.24; Rfree = 0.26). The structure revealed a typical Fc homodimer with N-
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glycans attached to CH2 domain residue Asn297 (Fig. 6A). Ordered electron 
density was observed up to a terminal galactose on the 6-arm and up to a terminal 
N-acetyl glucosamine on the 3-arm of the N-linked glycan, similar to wtFc 
structures and to SDALIE Fc (Fig. 6B). The GASDALIE substitutions were located 
in ordered electron density; however, the region containing Ala236 was disordered 
on both chains A and B (Fig. 6C). 
 In order to assess potential differences between GASDALIE Fc and wtFc 
structures, the CH3 domains of each Fc were aligned and the positions of the CH2 
domains were compared. We monitored CH2 domain separations in the various Fc 
structures by measuring distances between the Cα atoms at CH2 positions 238, 
241, 301, and 329 as described [54, 69]. As previously noted, wtFc structures 
exhibit relatively small structural differences, showing similar CH2 domain 
separations despite differences in crystal packing [54]. The separation between the 
CH2 domains of the GASDALIE Fc structure fell within range of the CH2 domain 
separations in wtFc (PDB 3DO3, 2DTS, 3AVE, 1HZH, and 4Q7D);, therefore the 
GASDALIE mutations did not greatly influence the overall CH2-CH2 domain 
arrangement in the unbound structure (Fig. 7). We also aligned the CH3 domains 
of the unbound GASDALIE Fc structure with the CH3 domains of the 2.5 Å SDALIE 
Fc structure (PDB 2QL1) [38]. SDALIE Fc was in a more open conformation than 
GASDALIE with a root mean square deviation (rmsd) of 5.8 Å calculated for the 
201 CH2 domain Cα atoms (Fig. 7).  
 We next compared the free GASDALIE Fc structure to the structure of 
GASDALIE solved in complex with FcγRIIIa. No notable differences were seen in 
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side chain conformations at the sites of the GASDALIE mutations; however, the 
CH2 domains of the bound GASDALIE Fc were in a more open conformation 
compared with the unbound form (Fig. 8) (rmsd of 2.3 Å calculated for the 202 Cα 
atoms of the CH2 domains of one Fc after alignment of the CH3 domains in each 
structure). However, the FcγRIIIa-bound GASDALIE Fc fell within the range of CH2 
domain separations for receptor-bound Fc structures (Fig. 8). This result was 
expected since previously-solved complexes of afucosylated and wtFc bound to 
FcγRIIIa did not show major changes in overall Fc conformation [29, 91]. 
 
DISCUSSION 
 IgG is a dynamic glycoprotein whose activities can be modulated with 
glycan and protein modifications to its Fc region. With introduction of the 
G236A/S239D/A330L/I332E substitutions in the Fc CH2 domain, binding to 
activating FcγR receptors is increased by 13-20–fold [33, 85]. Increased binding to 
activating FcγRs results in enhanced ADCC, of importance for developing 
therapeutic antibodies against cancer and infectious diseases [28, 29, 31, 35, 36]. 
Although a closely-related Fc mutant, SDALIE Fc, showed enhanced binding by 
~100-fold to the activating Fc receptor FcγRIIIa, it also enhanced binding to the 
inhibitory FcγRIIb receptor [35, 38]. By contrast, the GASDALIE Fc mutant 
selectively engages activating FcγRs with little to no enhanced binding to the 
inhibitory receptor [33, 85].  
 Here we present structures of GASDALIE Fc in its unbound state and in 
complex with the activating receptor FcγRIIIa. Although the SDALIE Fc structure 
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was in a more open conformation than wtFc structures with respect to the degree 
of separation of its CH2 domains [38], the unbound GASDALIE Fc fell within the 
range of CH2 domain separations in wtFc structures [38]. The more open 
conformation of SDALIE Fc compared with GASDALIE Fc may be important for its 
higher binding affinity for both activating and inhibitory FcγRs since notable 
changes in the side chain conformations of the of SDALIE substitutions were not 
observed when compared to GASDALIE Fc.  
 The binding interface between GASDALIE Fc and FcγRIIIa reveals key 
lysines in the receptor that interact with specific side chains of the Fc important for 
binding. FcγRIIIa Lys120 sits in a pocket containing Fc chain A residues Asp265 
and Asp239. Asp265, although not one of the GASDALIE substitutions in Fc, is 
important for interactions with FcγRs to mediate ADCC — when this residue is 
mutated (D265A), binding to both activating and inhibitory FcγRs is abrogated [92]. 
The introduction of Asp239 (the SD portion of the GASDALIE substitutions) may 
further stabilize the Asp265 (Fc)/Lys120 (FcγR) interaction, contributing to tighter 
binding of GASDALIE Fc than wtFc to FcγRIIIa. There is also an electrostatic 
interaction of Fc chain B residue Glu332 (the IE portion of the GASDALIE 
substitutions) with receptor residue Lys161 that is not observed in the 
wtFc:FcγRIIIa complex. Electrostatic interactions with this receptor lysine may also 
contribute to the increased affinity for GASDALIE Fc compared with wtFc.  
  Modeling of GASDALIE Fc bound FcγRIIb, along with the GASDALIE 
Fc:FcγRIIIa structure described in this work suggests the site of the G236A 
mutation in Fc (the GA portion of the GASDALIE substitutions) is located at the 
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FcγR binding site, slightly disrupting binding to activating, as well as inhibitory, 
receptors. Additionally, analysis of these structures gave insight on how each 
GADALIE substitution affected binding to each receptor. Introduction of Asp239 
(SD of GASDALIE Fc) in both chains A and B of GASDALIE Fc results in 
increased electrostatic interactions or hydrogen bonding with residues in FcγRIIb 
and FcγRIIIa. Although Leu330 (AL of GASDALIE Fc) did not play a role in the 
binding interface of GASDALIE Fc with any of the FcγRs, it is important in selecting 
for ADCC over complement-dependent cytotoxicity (CDC). This preference may 
result from the Leu330 substitution being close to the C1q binding site, disrupting 
binding of this protein to IgGs [35, 37, 93]. Substitution of Ile332 for Glu332 (IE 
substitution in GASDALIE Fc) results in increased electrostatic interactions with 
FcγRIIIa, but not with the other FcγRs. Comparison of FcγR affinities for the 
SDALIE mutant Fc compared with the GASDALIE Fc showed that substitution of 
Gly236 for Ala236, that distinguishes SDALIE from GASDALIE Fc, decreased 
binding to both activating and inhibitory FcγRs [33, 35]. The GASDALIE 
Fc:FcγRIIIa structure and homology models of GASDALIE Fc and wtFc bound to 
FcγRIIb show that the decrease resulting from the introduction of the G236A 
substitution may result from disruption of hydrogen bonds at the interface between 
FcγRIIIa and FcγRIIb. 
 The study presented gives structural insight on how the GASDALIE 
mutations enhance binding to FcγRIIIa. Further co-crystallization experiments with 
both FcγRIIa and FcγRIIb will be essential in further understanding how these 
mutations allow selection for activating Fc receptors.  
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FIGURE LEGENDS 
 
Figure 1. Reducing SDS-PAGE gel of FcγRIIIa ectodomains expressed in HEK-
293 cells (A) Unmodified FcγRIIIa. (B) FcγRIIIa with glycosylation sites at N38, 
N74, and N169 removed (FcgRIIIa-N45N162). (C) FcγRIIIa-N45N162 expressed in 
cells treated with 2.5µM kifunensine.  
 
Figure 2. Front view of the GASDALIE Fc:FcγRIIIa complex and interfaces at chain 
A and B of Fc:FcγR complex structures. (A) The D1 and D2 domains of FcγRIIIa 
are pink; the Fc CH2 domains are blue shown as cartoon ribbon diagrams; glycans 
(blue) are shown as sticks and G236/S239D/A330L/I332E mutations (red) are 
shown as spheres (left). Comparison of interfaces in the GASDALIE Fc–FcγRIIIa 
and fucosylated Fc–FcγRIIa structures. (B) Chain A of wtFc (PDB 3SGJ) (right) 
and GASDALIE Fc (left) bound to FcγRIIIa. (C) Chain B of wtFc (right) GASDALIE 
Fc (left) bound to FcγRIIIa. Electrostatic interactions (red) and hydrogen bonds 
(yellow) are shown as dashes. Residues that do not participate in hydrogen bonds 
or electrostatic interactions are shown in gray.  
 
Figure 3. 2Fo-Fc electron density (contoured at 0.7σ) from an annealed omit map 
calculated in the regions of: (A) Asn297-linked glycans on FcγRIIIa-bound 
GASDALIE Fc, (B) Asn45 and Asn162-linked glycans on FcγRIIIa, and (C) the 
G236/S239D/A330L/I332E mutations. 
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Figure 4. Comparison of GASDALIE Fc complexes with FcγRIIb and FcγRIIIa. 
(A,B) alignment of the D2 domains of FcγRIIb (PDB 1FCB, yellow) and FcγRIIIa 
(magenta) in the GASDALIE Fc:FcγRIIIa complex structure. The position of 
FcγRIIb was generated using homology modeling as described in the text. (C) 
Sequence alignment of the three FcγR receptors (ClustalW2).  
 
Figure 5. Comparison of the interfaces of GASDALIE Fc with FcγRIIb and FcγRIIIa. 
(A) Front view of the GASDALIE Fc:FcγRIIb homology model. The D1 and D2 
domains of FcγRIIb are yellow; the Fc CH2 domains are blue shown as cartoon 
ribbon diagrams; glycans and G236/S239D/A330L/I332E mutations (red) are 
shown as spheres (B) Chain A of wtFc (PDB 3SGJ) (right) and GASDALIE Fc (left) 
bound to FcγRIIb. (C) Chain B of wtFc (right) GASDALIE Fc (left) bound to 
FcγRIIb. Electrostatic interactions (red) and hydrogen bonds (yellow) are shown as 
dashes. Residues that do not participate in hydrogen bonds or electrostatic 
interactions are shown in gray. 
 
Figure 6. 2.4 Å crystal structure of unbound GASDALIE Fc. (A) CH2 and CH3 
domains shown as a ribbon diagram and glycans shown as sticks. (B-C) 2Fo-Fc 
electron density (contoured at 0.7σ) from an annealed omit map calculated in the 
regions of: (B) Asn297-linked glycans on chains A and B of GASDALIE Fc, and (C) 
the G236/S239D/A330L/I332E mutations. 
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Figure 7. Alignment of wtFc structures (PDB IDs: 3DO3, 2DTS, 3AVE, 4Q7D, 
1HZH, gray) with SDALIE Fc (PDB 2QL1, blue) and the GASDALIE Fc (this study, 
cyan). *SDALIE Fc crystallized with one Fc chain in the asymmetric unit, therefore 
chain B of the Fc homodimer was generated by two-fold symmetry. 
 
Figure 8. Comparison of CH2 domain separations in free Fc and complexed Fc 
structures. Left: location of Cα atoms for Pro238, Phe241, Arg301, and Pro329 
(red spheres) and Asn297 (blue spheres) indicated on the CH2 domains of wtFc 
(PDB 3AVE). CH2 domain separation in individual Fc structures was evaluated by 
measuring distances (dotted lines) between the corresponding red spheres on 
each chain. Right: Alignment of the CH3 domains of GASDALIE Fc, SDALIE Fc 
(PDB 2QL1), the Fc in the GASDALIE Fc:FcγRIIIA complex (this study), and the Fc 
regions in Fc:FcγRIIIa complex structures (PDB IDs: 3SGJ, 3SGK, 3AY4, 1E4K, 
1T89, and 1T83).  
 
 
 
 
 
 
 
 
  
76 
METHODS 
 
Protein Expression and Purification 
 The S239D/A330L/I332E (SDALIE), G236A/S239D/A330L/I332E 
(GASDALIE) and G236R/ L328R (GRLR) mutations were introduced by site-
directed mutagenesis in a pcDNA3.1 vector containing the IgG1 Fc gene (Agilent 
Technologies). Additionally the GASDALIE mutation was introduced into anti-HIV1 
antibody, 3BNC117. IgG, Fc, and FcγR proteins were expressed in transiently-
transfected HEK 293-6E suspensions as described previously [63, 72]. IgG and Fc 
proteins were then isolated from harvested supernatants using protein A 
chromatography (GE Healthcare) followed by size exclusion chromatography in 25 
mM Tris-Cl pH 7.5, 100 mM NaCl on a Superdex 200 10/300 gel-filtration column 
(GE Healthcare). FcγR proteins were isolated from supernatants using affinity 
chromatography (HisTrap, GE Healthcare) followed by size exclusion 
chromatography using the buffer described above.  Fractions to the corresponding 
proteins were pooled and used for surface plasmon resonance (SPR) and 
crystallographic studies. 3BNC117 IgG was papain digested to isolate the Fc 
region containing the GASDALIE mutation (G236A/S239D/A330L/I332E) and was 
used to crystallize GASDALIE Fc alone. 
 
 Site directed mutagenesis was used to remove three of five potential N-
linked glycosylation sites on FcγRIIIa (N38, N74, N169) by changing asparagines 
to glutamines to make N38Q, N74Q, N169Q substitutions, as described for 
  
77 
previous structural studies of FcγRIIIa [29]. Potential N-linked glycosylations sites 
at sites 45 and 162 were retained due to their effects on protein expression and 
binding affinity, respectively [29, 30]. C-terminally 6x-His tagged FcγR ectodomains 
FcγRIIa (residues 1-113) and FcγRIIIa (residues 1-113) were expressed in 
transiently-transfected HEK293 cells as described for Fc proteins and isolated from 
supernatants using a HisTrap HP affinity column (GE Healthcare) followed by size 
exclusion chromatography in 25 mM Tris-Cl pH 7.5, 100 mM NaCl on a Superdex 
200 16/ 60 gel-filtration column (GE Healthcare). To reduce carbohydrate 
heterogeneity that might impede crystallization, 2.5 µM kifunensine was added 
immediately before transfection of cells to inhibit processing of high-mannose N-
linked glycans to their complex forms [94]. 
 
Crystallization and data collection 
 Crystals of GASDALIE Fc (space group P212121; a = 49.32 Å, b = 79.13 Å, 
c = 137.62 Å; one Fc dimer per asymmetric unit) were grown in sitting drop vapor 
diffusion by mixing equal volumes of GASDALIE Fc (7.36 mg/ml) with a solution 
containing 0.2 M ammonium formate and 20% (w/v) PEG 3350 at 20°C. Crystals 
were cryopreserved in well solution supplemented with 30% glycerol. Data were 
collected to 2.4 Å resolution at beamline 8.2.1 of the Advanced Light Source (ALS) 
at Lawrence Berkeley National Laboratory (LBNL).  
 Crystals of GASDALIE Fc:FcγRIIIa (space group P212121; a = 74.38 Å, b = 
94.50 Å, c = 108.67 Å; one complex per asymmetric unit) were grown in sitting 
drop vapor diffusion by mixing equal volumes of protein (10 mg/ml) with a solution 
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containing 0.04 M potassium dihydrogen phosphate and 16% (w/v) PEG 8000 at 
20°C. The complex crystals were cryopreserved in well solution. Data were 
collected for GASDALIE Fc alone and GASDALIE Fc:FcγRIIIa complex to 3.1 Å 
resolution at beamline 8.2.1 of the Advanced Light Source (ALS). 
 
Data Processing and Structure Determination 
 Diffraction data were processed, indexed, integrated and scaled using 
iMosflm [73] POINTLESS and SCALA, respectively [74, 75]. We used I/σI ratios 
and completeness of the highest resolution shell in addition to the criterion that the 
CC1/2 statistic (correlation coefficient between two random halves of the data set) 
should be greater than 10% [76] to determine the high-resolution cutoff for 
datasets. We used Phenix [77] to compute CC1/2 values. Structures were solved by 
molecular replacement using PHASER [78] and published Fc and Fc:FcγRIIIa 
structures as search models (PDB codes 4BYH for determining the GASDALIE Fc 
structure and 3SGK for determining the GASDALIE Fc:FcγRIIIa complex 
structure). Modeling was done using COOT [79]. Crystallographic refinement was 
done using the Phenix crystallography package [77] by refining individual B factors 
for GASDALIE Fc and group B factors for the lower-resolution GASDALIE 
Fc:FcγRIIIa structure. We used PyMol [80] for superposition calculations and 
molecular representations. 
 The GASDALIE Fc model (Rfree = 25.6%; Rwork = 23.5%) included 416 
protein residues in the GASDALIE Fc dimer (Leu235 – Ser444 on chain A and 
Gly237 – Ser444 on chain B), 18 glycan residues (GlcNAc1-Gal6, Fuc12 on chain 
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A and GlcNAc1-GlcNAc8, Fuc12 on Chain B), and 105 water molecules. No 
electron density was observed for residues Thr225 and Cys226 of the Fc hinge or 
for Man7-NeuNAc10 or Gal9-NeuNAc11 in the N-linked glycans of chain A or B, 
respectively.  
 The GASDALIE Fc:FcγRIIIa complex (Rfree = 29.2%; Rwork = 27.4%) 
included 421 protein residues in the GASDALIE Fc dimer (Leu234-Ser444 on 
chain A and Pro232-Leu443 on chain B), 17 glycan residues on Fc (GlcNAc1-Gal6 
on chain A and GlcNAc1-GlcNAc8, Fuc12 on Chain B), 169 protein residues in the 
FcγRIIIa ectodomain, GlcNAc1 and GlcNAc2 attached to Asn162, and GlcNAc1 
attached to Asn45.  
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FIGURES AND TABLES 
Table 1.  Data collection and refinement statistics 
 GASDALIE Fc:FcgRIIA GASDALIE Fc Resolution range (Å) 71.31  - 3.10 (2.98  - 2.88) 46.43  - 2.39 (2.48  - 2.39) 
Space group P 21 21 21 P 21 21 21 
Unit cell (a,b,c; Å) 74.38, 94.50, 108.67 49.32, 79.13, 137.62 
Total reflections 275073 (21164) 751679 (75586) 
Unique reflections 17985 (1754) 22054 (2176) 
Multiplicity 15.3 (12.1) 34.1 (34.7) 
Completeness (%) 100.00 (100.00) 100.00 (100.00) 
Mean I/sigma(I) 7.95 (0.25) 30.00 (3.70) 
Wilson B-factor 78.79 45.6 
R-merge 1.091 (12.02) 0.8385 (1.926) 
R-meas 1.128 0.8516 
CC1/2 0.813 (0.213) 0.759 (0.767) 
CC* 0.947 (0.593) 0.929 (0.932) 
R-work 0.2738 (0.4865) 0.2346 (0.3129) 
R-free 0.2915 (0.4927) 0.2557 (0.3142) 
Number of non-hydrogen atoms 4864 3631 
  macromolecules 4612 3306 
  ligands 252 220 
  water 0 105 
Protein residues 600 418 
RMS(bonds) 0.016 0.026 
RMS(angles) 1.42 1.61 
Ramachandran favored (%) 95 98 
Ramachandran outliers (%) 0.17 0.24 
Clashscore 26.52 19.99 
Average B-factor 40.4 57.9 
  macromolecules 38.3 56.1 
  ligands 79.5 49.7 
Statistics for the highest-resolution shell are shown in parentheses. 
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Figure 1. Reducing SDS-PAGE gel of FcγRIIIa ectodomains 
expressed in HEK-293 cells.   
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Figure 2. Comparison of interfaces in the GASDALIE Fc:FcγRIIIa and 
wtFc:FcγRIIIa (PDB 3SGJ) structures 
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Figure 3. 2Fo-Fc electron density (contoured at 0.7σ) from annealed 
omit maps calculated in the vicinity of (A) the Asn297-linked glycans 
on FcγRIIIa-bound GASDALIE Fc, (B) the Asn45- and Asn162-linked 
glycans on FcγRIIIa, and (C) the G236/S239D/A330L/I332E 
substitutions. 
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Figure 4. Comparison of FcγRIIb and FcγRIIIa structures bound to 
GASDALIE Fc   
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Figure 5. Comparison of the interface of FcγRIIb and FcγRIIIa bound to 
GASDALIE Fc 
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Figure 6. (a) 2.4Å crystal structure of unbound GASDALIE Fc 
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Figure 7. Carbon-α alignment of wild type Fc structures (3DO3, 2DTS, 
3AVE, 4Q7D, 1HZH) with SDALIE Fc (2QL1) and GASDALIE Fc 
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Figure 8. Comparison of CH2 domain separations in free and 
complexed Fc structures 
 
 
 
 
 
 
 
 
 
 
PDB Protein Resolution (Å) SG Unit cell (a, b,c) Pro238(Å) Phe241(Å) Arg301(Å) Pro329(Å) 
N/A GASDALIE Fc 2.4 P212121 49, 79, 138 19 22 33 24 
2QL1 SDALIE Fc 2.5 C2221 50, 149, 76 28 29 37 39 
N/A GASDALIE Fc: FcgRIIIA 3.1 P212121 74, 95, 108 25 26 38 31 
3SGJ  fucosylated  Fc: FcgRIIIA 2.2 P212121 67, 89, 140 26 26 37 32 
3SGK afucosylated Fc: FcgRIIIA 2.4 P212121 67, 88, 141 26 27 37 33 
3AY4 afucosylated Fc: FcgRIIIA 2.2 P41212 77,77,350 25 26 37 31 
1E4K fucosylated Fc: FcgRIIIB 3.2 P6522 115, 115, 299 25 26 37 30 
1T89 fucosylated Fc: FcgRIIIB 3.5 P6522 115, 115, 301 25 26 37 31 
1T83 fucosylated Fc: FcgRIIIB 3.0 P212121 73, 102,123 25 26 37 31 
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Chapter 4: Investigation of the Proposed Interaction of 
DC-SIGN with Sialylated Fc 
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INTRODUCTION 
Recently there have been conflicting reports surrounding the mechanism of action 
of intravenous immunoglobulin G (IVIG) in the anti-inflammatory pathway.  
Previous studies suggested that the activity of IVIG is due to a small percentage of 
IgGs with terminally sialylated N-linked glycans [43, 46, 70]. Based on published 
results, sialylation resulted in an increased affinity of IgG Fcs to human receptor 
DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin) and its mouse orthologue SIGN-R1 (specific intercellular adhesion 
molecule-3-grabbing nonintegrin-related 1) thereby initiating a cascade of events 
leading to release of cytokines IL-4 and IL-33 by regulatory macrophages and 
basophils respectively, ultimately causing an upregulation of FcγRIIb on effector 
immune cells, increasing the threshold of activation for these cells [46, 70, 95]. 
This leads to suppressed inflammation.  
            In vivo experiments show that DC-SIGN is important in the anti-inflammatory 
 pathway initiated by IVIG/sialylated Fcs [9, 46, 70]. When splenic macrophages 
were depleted in mice and inflammation was induced using a K/BxN serum 
(described in Chapter 1), there was no protection against inflammation, therefore 
receptors known to be expressed on the surface of splenic macrophages 
(MARCO, CD169, and SIGN-R1) became of interest [70, 96-98]. Out of these 
receptors, the deletion of only SIGN-R1 disabled the anti-inflammatory effect of 
IVIG and α2,6-linked sialylated Fc. In addition, blocking of this receptor abrogates 
IVIG/sialylated Fcs anti-inflammatory effect in vivo [46, 70]. 
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             Binding studies were performed in order to determine if there was direct 
binding of α2,6-linked sialylated Fc to SIGN-R1 [61, 70, 95]. SIGN-R1+ 
macrophages and SIGN-R1-/- macrophages from mice were pulsed with either 
α2,6-linked sialylated Fc or asialylated Fc. Binding was observed between sFc to 
SIGN-R1+ cells and not SIGN-R1 -/- cells [70]. Additionally, sialylated Fc had a 10-
fold decrease in binding affinity to FcγRs. In a similar binding assay, asialylated 
Fcs bound macrophages only when FcγRs were expressed on the surface – they 
did not bind SIGN-R1 [70]. Similar results were obtained when using hDC-SIGN+ 
macrophages. These results suggested glycosylation state defines the effector 
function of an IgG Fc. Introduction of an F241A mutation in the CH2 domain of IgG 
Fc also causes protection from inflammation and an increase in IgG Fc binding 
affinity to DC-SIGN in in vivo mouse arthritis models [95]. A recent study showed 
binding of sialylated but not asialylated Fc to DC-SIGN, however both asialyated 
and sialylated F241A Fc were able to bind by ELISA [61, 95]. These findings 
suggest that a change in conformation of the protein or oligosaccharide chain 
results in an introduction of a binding site for DC-SIGN. 
 
           Based on the studies presented above we attempted to determine if 
structural changes occur once an Fc N-linked glycan is sialylated or mutated 
(F241A), causing an increase in affinity to DC-SIGN and if these structural 
changes occur in the DC-SIGN, binding site, using X-ray crystallography. This 
would provide insight, at atomic resolution, into protein conformational changes as 
well as carbohydrate-protein and protein-protein interactions between sialylated Fc 
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or F241A Fc and DC-SIGN. We also aimed to perform equilibrium gel filtration 
experiments to determine the stoichiometry of the sFc: DC-SIGN interaction. 
Binding of both the extracellular domain (ECD) and carbohydrate recognition 
domain (CRD) of DC-SIGN to sialylated or F241A mutant Fc by surface plasmon 
resonance (SPR) were not demonstrated although HIV glycoprotein gp120 
showed signs of binding to this receptor. Due to the inability to demonstrate 
binding between DC-SIGN and sFc or F241A Fc, co-crystallization attempts and 
stoichiometry experiments were not pursued. Here, we present the results of our 
binding experiments and a review of results related to binding studies of this 
receptor with sialylated Fcs (see chapter 2 for structural characterization of 
disialylated Fc and F241A Fc). 
 
Table 1. Affinity of sialylated Fc and asialylated Fc to SIGN-R1, hDC-SIGN and 
hFcγRIIb* 
 
Receptor α2,6 sialyalted Fc asialylated Fc 
SIGN-R1 2.7 x 10-6M n.b 
hDC-SIGN 3.6 x 10-6M n.b 
hFcγRIIb 1.5 x 10-6M 1.6 x 10-6M 
*Adapted from Anthony et al. PNAS 2008 
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METHODS/ RESULTS 
Protein Expression/ Purification 
DC-SIGN ECD and CRD proteins were expressed and purified as previously 
described [47]. Sialylated Fc was derived from papain digested IDEC-114 
monoclonal Ab. In order to isolate the Fc, the cleaved IgG was run over a size 
exclusion column and purified with protein G agarose beads. The Fc fragment was 
then galactosylated with β1-4 galactosyltransferase and sialylated with α2-6 
sialyltransferase in vitro as previously described [61, 95]. Sialylated Fc Fragments 
were then purified with protein G agarose beads to remove enzymes. This protein 
was further purified by size exclusion chromatography on a Superdex 200 10/300 
column (GE Healthcare). 
 
Surface Plasmon Resonance Analysis to Detect Binding of 
Sialylated Fc and F241A Fc to DC-SIGN ECD and CRD 
Surface plasmon resonance experiments were performed on a Biacore T100 at 
25°C with HBS-P buffer (10mM Hepes pH6.8, 150mM NaCl, 0.05% Tween20) as 
a running buffer. DC-SIGN CRD or ECD was immobilized on a CM5 chip at 400 
RU, 900 RU, and 1300RU for DC-SIGN CRD (AA), DC-SIGN ECD (AP), and DC-
SIGN ECD (AA), respectively. Sialylated Fc and F241A Fc were injected over flow 
cells containing either ECD or CRD at a flow rate of 10µl min-1 for 60 seconds.  A 
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Figure 1. Surface plasmon resonance analysis of the interaction of DC-SIGN ECD 
or CRD with sialylated Fc and F241A Fc. Overlay of binding of 30µM of gp120 (A), 
F241A Fc (B), or sFc (C) to DC-SIGN ECD expressed at Caltech* (red) or 
Rockefeller University** (blue). (D) Binding of 30µM sialylated Fc to DC-SIGN CRD 
expressed at Caltech* (cyan).    
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blank reference flow cell was used to correct bulk refractive index. Binding of 
sialylated Fc to DC-SIGN ECD or CRD was not detected although binding of  
positive control (gp120) to DC-SIGN ECD was detected. We also did not see 
binding of F241A Fc to DC-SIGN ECD. 
 
CONCLUSION 
We could not reproduce any of the published results stating that there is direct 
binding of sialylated Fc to DC-SIGN ECD or CRD therefore we decided not to 
pursue equilibrium gel filtration experiments to determine stoichiometry or co-
crystallization of the DC-SIGN:sialylated Fc complex. Our use of gp120 as a 
positive control showed that the protein produced at Rockefeller University and the 
protein expressed here at Caltech were indeed functional. These results were 
surprising since our collaborators showed direct binding of sialyalted Fc to DC-
SIGN using cell binding assays and ELISA experiments [61, 70, 95].  
                 A recent publication showed that IVIGs interaction with DC-SIGN is 
independent of Fc glycoform — sialylated Fc does not bind DC-SIGN [99]. Similar 
to our results, the authors were able to see binding of heavily mannosylated gp120 
to DC-SIGN. Hypersialylated, desialylated (neuraminidase treated), and 
deglycosylated serum IgG bound with similar affinity to DC-SIGN as unmodified 
serum IgG by ELISA. In addition, wtFc expressed recombinantly and 
hypersialylated Fc showed no binding to DC-SIGN, contradicting previously 
published results. Affinity to activating receptor FcγRIIIa was also not affected by 
sialylation. Serum IgG also did not outcompete gp120 in a competition-binding 
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assay to DC-SIGN CRD.  
            Although the key players involved in the anti-inflammatory pathway have been 
 identified, their exact role remains unclear. Contradicting reports in recent 
publications are an indicator that further studies are needed to characterize these 
receptors and signaling proteins. In addition to studies showing that binding of 
sialylated Fc to DC-SIGN does not occur, recent in vivo studies show that 
protection from inflammation in Collagen-antibody and K/BxN serum-induced 
arthritis mouse models is independent of sialylation of the Fc; however IVIG Fc is 
able to show a protective effect [99, 100]. Also, there have been recent studies 
showing that IL-4 producing basophils are not required for the protective effect of 
IVIG in both Collagen and K/BxN serum-induced arthritis models in addition to IL-
33 inability to mediate basophil expansion in vivo [100, 101]. These results 
contradict the pathway proposed by Ravetch and colleagues based on their in vivo 
studies: sialylated Fc binds DC-SIGN on the surface of regulatory macrophages 
causing a release of cytokine IL-33. IL-33 binds to its receptor IL-33Rα located on 
the surface of basophils causing these cells to expand and release IL-4. IL-4 binds 
its receptor, IL-4α, on the surface of effector macrophages, causing an 
upregulation of the inhibitory receptor FcγRIIb and an increase in the threshold of 
activation of these cells. Most of the results in publications from the Ravetch group 
could not be reproduced by any of these groups. Due to the discrepancies in the 
research concerning the role of IVIG and proteins involved the anti-inflammatory 
pathway, further investigation is essential prior to structural characterization.  
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Chapter 5: Conclusion 
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Immunoglobun G (IgG) antibodies are involved in both pro-inflammatory 
and anti-inflammatory activities. For my thesis work, I have studied the structural 
mechanisms by which IgG Fc can mediate both pro- and anti-inflammatory 
immune pathways. A well-known anti-inflammatory activity of IgG is mediated by 
intravenous immunoglobulin (IVIG), which is effective in treating a wide range of 
autoimmune and inflammatory disorders although its mechanism of action is 
poorly understood. In vivo studies showed that the activating factor in IVIG therapy 
are IgG Fcs with terminally sialylated glycans [8, 9, 43, 44, 46, 55, 70]. 
Additionally, introduction of an F241A substitution in the Fc CH2 domain 
demonstrated anti-inflammatory effects similar to sialylated Fc [95]. Our structural 
studies gave insight on how sialylation or an F241A mutation influences 
conformation of the Fc protein leading to the switch from pro- to anti-inflammatory 
activity.  
We showed that sialylated Fc could adopt both “open” and “closed” states 
in the same crystal. This has not been seen in the many asialylated Fc structures 
in the PDB suggesting an increase in conformational flexibility of sialylated Fc that 
may facilitate its anti-inflammatory properties [54]. Introduction of the F241A 
substitution may result in sialylated Fc properties since this amino acid substitution 
resulted in an increase of sialylated products, which may lead to increased 
flexibility [54]. Thus, our results suggest that increased flexibility correlates with 
sialylation of Fc, whether by enzymatic sialylation of Fc glycans or by the F241A 
substitution.  
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It was previously proposed that sialylation results in a conformational 
change allowing Fcs to bind to DC-SIGN, a lectin that exists as a tetramer on the 
surface of splenic macrophages [46, 47, 70]. The proposed sialylated Fc initiated 
anti-inflammatory pathway is as follows: binding between sialylated Fc and DC-
SIGN leads to the release of cytokine IL-33 from DC-SIGN+ splenic macrophages. 
Released IL-33 binds its receptor, IL-33Rα, on the surface of basophils leading to 
activation of these cells, triggering the release of cytokine IL-4. IL-4 binds its 
receptor, IL-4Rα, located on the surface of effector macrophages leading to an 
upregulation of the inhibitory receptor FcγRIIb thereby increasing the threshold of 
activation of these effector cells [46]. To support the hypothesized interaction 
between sFc and DC-SIGN, cell-based experiments were performed that showed 
selective binding of sialylated Fc over asialylated Fc to DC-SIGN+ or SIGN-R1+ 
cells [61, 70]. These experiments could be interpreted to show that sFc binds to 
DC-SIGN and SIGN-R1 at the surface of cells either through a direct interaction or 
through an interaction with an unidentified cell-surface protein. However, the DC-
SIGN+/SIGN-R1+ cells used in these binding experiments were pulsed with 
sialylated or asialylated Fc at 37°C for one hour, a specific change from most/all 
cell binding experiments in which the cells are incubated with a potential ligand at 
4˚C in order to prevent endocytosis and therefore measure only cell surface 
binding events [50, 61, 70]. Indeed, previous SIGN-R1 binding studies were 
conducted using cells at 4˚C [50]. Thus it is not possible to interpret these results 
as evidence for a specific interaction, whether direct or indirect, between sFc and 
DC-SIGN/SIGN-R1 [61, 70]. Other experiments using purified proteins were 
  
101 
conducted to investigate whether DC-SIGN/SIGN-R1 could bind directly to sFc. 
ELISA experiments reported selective binding of purified sialylated and asialylated 
F241A Fc over desialylated Fc to DC-SIGN and its mouse orthologue SIGN-R1 
[95]. However, we were unable to detect binding of the DC-SIGN carbohydrate 
recognition domain (CRD) or the DC-SIGN tetrameric extracellular domain (ECD) 
to sialylated Fc or to the F241A mutant Fc by surface plasmon resonance (SPR) 
experiments or ELISAs using the same proteins that were used in the experiments 
reporting a direct binding interaction[61, 95]. Our results are in agreement with 
recent published studies that also contradict binding studies in Fiebiger et al. by 
showing that sialylated Fc and wtFc did not bind DC-SIGN [95, 99].  
 
Although we have shown that neither sialylated nor F241A Fc interacts 
directly with DC-SIGN, previous studies have shown that deletion of this receptor 
abrogates the IVIG initiated anti-inflammatory pathway [46, 70]. While these 
findings show that this receptor is essential to IVIG activity, our results and 
published results indicated that direct binding of Fcs to DC-SIGN does not occur 
[99]. The increase in conformational flexibility may be important for binding another 
receptor in this pathway, perhaps FcγRIIb. FcγRIIb is the inhibitory receptor located 
on surface of B cells, macrophages, neutrophils, dendritic cells, and basophils [2]. 
Previous studies have shown that deletion of this receptor abrogates IVIG activity, 
which may suggest direct binding of sialylated Fc or F241A Fc to FcγRIIb [46]. The 
increase in flexibility resulting from sialylation or the F241A mutation may lead to 
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an increase in an abundance of a specific conformation of Fcs highly selective for 
FcγRIIb. 
 
 The IVIG pathway is poorly understood, and contradictory studies of its 
mechanism of action are continually reported [99-101]. Further investigations to 
identify the key players in this pathway are necessary to elucidate the mechanism 
of action of this therapy. Additionally, further studies to investigate flexibility of 
sialylated Fc and F241A Fc using a methods such as electron paramagnetic 
resonance (EPR) spectroscopy could provide insight into the flexibility of Fcs and 
the minimum and maximum distances between the CH2 domains of the Fc in 
solution. Methods to increase the flexibility of the Fc using both glycan and protein 
modifications need to be explored to understand the importance in destabilizing 
the Fc to produce anti-inflammatory effects and may be used to produce 
therapeutic antibodies to treat autoimmune and inflammatory disorders. Once the 
binding partners of sialylated Fc and F241A Fc are identified, screening of Fc 
mutants to enhance affinity to that receptor should be performed and correlated to 
the anti-inflammatory effects in vivo.  
 
My thesis studies also focused on understanding the role of Fc 
modifications that affect the pro-inflammatory activities of IgGs. Many efforts were 
made to modify IgG Fc to enhance antibody dependent cell-mediated cytotoxicity 
(ADCC), which has been important for development and optimization of 
therapeutic antibodies against various cancers [11, 28, 33, 35, 36, 38, 88]. 
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Previous studies showed that glycan modifications (e.g., afucosylation) or amino 
acid substitutions in the CH2 domain of IgG Fcs could enhance binding to 
activating FcγRs (both FcγRIIa and FcγRIIIa) that are located on the surface of 
immune cells – resulting in enhanced ADCC [27, 29, 33, 35]. Two promising 
candidates were Fcs with the set of mutations S339D/A330L/I332E (SDALIE) or 
G236A/S239D/A330L/I332E (GASDALIE) [33, 35]. SDALIE Fc enhanced binding 
to activating receptor FcγRIIIa by 170-fold and to the inhibitory receptor, FcγRIIb, 
by 40-fold, whereas GASDALIE Fc had a 20-fold enhancement to FcγRIIIa and 
little to no increase in binding to FcγRIIb [33, 35]. Introduction of the G236A 
substitution that distinguishes SDALIE from GASDALIE did not increase binding to 
the inhibitory receptor compared with wtFc, but GASDALIE Fc still exhibited 
enhanced binding to activating receptors making it a desirable candidate for 
enhancement of ADCC without increasing inhibitory FcγRIIb-related pathways [33, 
35].  
We solved a structure of GASDALIE Fc bound to the ectodomain of the 
activating receptor FcγRIIIa, which provided insight on how these mutations 
influenced binding to FcγRs. We found increased electrostatic interactions and 
hydrogen bonding at the interface between GASDALIE Fc and FcγRIIIa not seen 
in a wtFc:FcγRIIIa complex structures. This structure can aid in designing better 
mutants to selectively bind activating receptors thereby optimizing therapeutic 
antibodies against cancer. There are antibodies used today that recognize specific 
tumor antigens for the treatment of various cancers. Rituximab, Trastuzumab and 
Cetuximab are among the antibody-based immunotherapies used today to treat 
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non-Hodgkin lymphoma, breast cancer, and colorectal cancer, respectively [2]. 
Introducing the GASDALIE mutations in the CH2 domains of these therapeutic 
antibodies may be used to increase the clearance of the associated tumor cells 
resulting from an enhancement of ADCC. Consequently, this may result in a lower 
dose of antibody needed in addition to decreased amount of treatment time. 
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